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1. Abstract 
 
Background:  
Activins belong to the extended transforming growth factor beta superfamily of 
cytokines which play key roles in e.g. embryonic development, inflammation, 
growth, differentiation and death of cells to mention just some of their functions. 
Until now the function and signaling mechanism of activin βE, the latest activin 
subunit to be discovered, which is prominently expressed in the liver, is unclear. 
Activin E was found downregulated in hepatocellular carcinoma and elevated in 
multiple leukemia cell lines. The aim of the present study was to investigate activin E 
signaling in hepatoma and leukemia cell models and how it could contribute to 
malignancies.  
 
Methods:  
A dual approach was conducted in order to investigate activin E functions in 
malignant cells. For establishment of stable clones with increased activin E level, 
expression vectors were generated and transfected via lipofection into cell lines with 
low endogenous activin E levels. At the same time a lentivirus-mediated knockdown 
of activin βE was performed in cell lines expressing high endogenous levels of 
activin E. Additionally a baculovirus expression system was used for the production 
of histidin-tagged activin E, because recombinant activin E is still not available 
commercially. Phenotypic differences between stable clones and their respective 
controls were examined by several in vitro assays measuring proliferation, viability, 
migration, anchorage independent growth, clonogenicity and cell cycle distribution. 
To find potential pathways activin E might be involved in, 4x44k expression arrays 
were carried out.  
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Results:  
In MTT and proliferation assays no stimulation or inhibition of proliferation and 
viability were obtained when activin E levels were elevated or decreased. The cell 
cycle distribution did not differ between stable clones and control cells. In contrast, 
Activin βE reduced anchorage-indepent growth in three-dimensional soft agar 
assays and clone size in clonogenic assays. Migration assays revealed a slightly 
reduced motility in lateral migration and increased ability to pass through pores of 
transwell membranes when activin E levels were elevated. Baculovirus-produced 
Histidin-tagged activins were able to dimerize but bioactivity of the recombinant 
proteins could not be achieved, since the generated recombinant activin A could not 
activate Smad2/3 phosphorylation. The expression array revealed that several 
apoptosis-related genes were upregulated in activin E overexpessing cells, and the 
related cytokine activin A was strongly down-regulated in one of the hepatome cell 
lines. Several other genes involved in different signalling cascades were regulated 
and need further investigation.  
 
Conclusion: 
Long-term examination of activin E overexpressing cells reveals anti-proliferative 
effects, especially in in vivo like experiments. Activin E crosstalks with multiple 
signaling cascades but cannot be connected to a certain receptor, thus signaling 
mechanisms need further investigation.  
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2. Zusammenfassung 
 
Hintergrund:  
Aktivine gehören zur TGF-β Familie an Wachstumsfaktoren und spielen eine 
wichtige Rolle in der Embryonalentwicklung, in Entzündungsvorgängen, in 
Wachstum, Differenzierung und Zelltod um nur einige Funktionen zu erwähnen. Bis 
heute sind die Funktion und der Signaltransduktionsmechanismus von Aktivin βE, 
der als letztes entdeckten Untereinheit, welcher vor allem in der Leber exprimiert 
wird, unklar. Aktivin E ist herabreguliert im Leberzellkarzinom und überexprimiert 
in vielen Leukämie Zelllinien. Das Ziel dieser Studie war, den Signalmechanismus 
von Aktivin E in Hepatom und Leukämie Zelllinien zu untersuchen und 
herauszufinden, wie es zum malignen Wachstum beiträgt.  
Methoden: 
Für die Untersuchung der Funktionen von Aktivin E in malignen Zellen wurde ein 
Doppelansatz durchgeführt. Für die Etablierung von stabilen Klonen mit erhöhter 
Aktivin E Expression wurden Expressionsvektoren generiert und durch Lipofektion 
in Zellen mit niedrigem endogenem Aktivin E transfiziert. Gleichzeitig wurde 
Aktivin E mittels sh-Lentiviren in Zelllinien mit relativ hoher Aktivin E Expression 
hinabreguliert. Zusätzlich wurde ein Baculovirus Expressionssystem angewendet, 
um rekombinantes Aktivin E zu produzieren, welches bis heute noch nicht 
kommerziell erhältlich ist. Mittels unterschiedlicher in vitro Assays wurden stabile 
Klone mit Kontrollzellen verglichen und auf phänotypische Unterschiede bezüglich 
Proliferation, Viabilität, Adhäsions-unabhängiges Wachstum, Klonogenität und  
Zellzyklusphasenverteilung untersucht. Um potentielle Signalkaskaden zu 
detektieren, in die Aktivin E involviert ist, wurden Expressionsanalysen mit 4x44k 
Expressionsarrays durchgeführt.  
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Ergebnisse: 
Überexpression oder verminderte Expression von Aktivin E zeigte in MTT- und 
Proliferationsuntersuchungen keine stimulierende oder inhibierende Wirkung auf  
die Proliferation oder Viabilität der jeweiligen Zelllinien. Die Verteilung der 
Zellzyklusphasen war ebenfalls unverändert zwischen stabilen Klonen und 
Kontrollzellen. Im Gegensatz dazu reduzierte eine Überexpression von Aktivin E die 
Proliferation im Soft Agar Assay für Adhäsions-unabhägiges Wachstum, und die 
Gröβe der Klone im Clonogenic Assay. In Migrationsassays hatten Aktivin E 
überexprimierende Zellen eine reduzierte laterale Motilität, jedoch eine erhöhte 
Fähigkeit durch Poren von Membranen zu wandern. Histidin-epitopmarkierte 
Aktivine konnten dimerisieren, aber eine Bioaktivität konnte nicht nachgewiesen 
werden, da das produzierte rekombinante Aktivin A keine Smad2/3 
Phosphorylierung auslösen konnte. Die Expressionsanalyse zeigte, dass einige in der 
Apoptose involvierte Gene durch Aktivin E hochreguliert wurden, während das 
verwandte Zytokin Aktivin A stark herab reguliert war. Diverse andere Gene, die in 
verschiedene Signalkaskaden involviert sind, waren zusätzlich stark reguliert und 
sollten weiter untersucht werden. 
 
Schlussfolgerung: Bei Langzeitversuchen mit Aktivin E überexprimierenden Zellen 
werden anti-proliferative Effekte beobachtet, vor allem in in vivo ähnlichen 
Experimenten. Aktivin E interagiert mit vielen Signalkaskaden ohne bisher einem 
bestimmten Rezeptor zugeordnet werden zu können.  
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3. Introduction 
 
3.1. TGF -β family 
 
The transforming growth factor beta (TGF-β), as a multifunctional growth factor, is a 
member of a superfamily of cytokines including TGF-β isoforms, activins, growth 
and differentiation factors (GDFs), bone morphogenetic proteins (BMPs), myostatin, 
Muellerian inhibiting substance (MIS) – and several others- , which are involved in a 
wide range of cellular processes  like proliferation, differentiation and apoptosis 
(Deli et al., 2008; Nagaraj et al., 2010). Discoveries demonstrate that cytokines of the 
TGF-β superfamily, which includes more than 40 ligands (Chen et al., 2006) also 
control embryonic development, wound healing (Zhang et al., 2004) and 
angiogenesis (Nagaraj et al., 2010). Surely, various other roles in growth and 
development have yet to be discovered.  
3.1.1.  TGF-β Signaling 
 
The canonical TGF-β signaling process is relatively simple (Figure 1). TGF-β signals 
through so called type I and type II serin/threonine kinase receptors (Fischer et al., 
2005). Ligand binding to the type II receptor leads to type I receptor recruitment and 
its phosphorylation due to the intrinsic kinase activity of the receptor (Nagaraj et al., 
2010; Zhang et al., 2004). Further on, the type I receptor phosphorylates receptor 
regulated cytoplasmatic effectors of the SMAD-family (R-SMAD) which then can 
associate with downstream signaling mediators, the so called Co-SMADs (Massague, 
2008). Activation of Co-SMADs through phosphorylation leads to translocation of 
the R-SMAD-Co-SMAD complex into the nucleus and regulation of the transcription 
of target genes (Massague, 2008). Through cross-talk with additional proteins, 
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however, the TGF-β receptors can activate multiple signaling pathways in a SMAD-
dependent or independent manner (Nagaraj et al., 2010).  
 
 
 
 
3.1.2. TGF-β functions in cancer 
 
Activation of TGF-β target genes can lead to pathological events like growth, 
invasiveness and metastasis of cancer cells (Fischer et al., 2005). It is thought that on 
the one hand TGF-β acts as a tumor suppressor with a growth inhibitory function in 
healthy epithelial cells or in early malignant stage by negatively regulating 
Figure 1: Schematic overview of SMAD-dependent TGF-β signaling 
(Schmierer et al., 2007). 
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proliferation (Fischer et al., 2005). In hepatocytes, for instance, TGF-β signaling leads 
to cell-cycle arrest and apoptosis (Oberhammer et al., 1991; Oberhammer et al., 1992). 
On the other hand TGF-β acts in a tumor promoting fashion on advanced cancer 
cells, it stimulates fibroblastoid cells for growth and the production of extracellular 
matrix. TGF-β, as an angiogenetic factor influences endothelial cells and induces 
angiogenesis (Fischer et al., 2005). Furthermore it has immunosuppressive properties, 
for instance through inhibition of T cell proliferation, and in consequence modulates 
the tumor stroma (Naber et al., 2008). The fact that TGF-β is not found in healthy 
adult liver, but overexpressed in HCC cells leads to the notion that there is an 
autocrine stimulation mechanism/machinery of TGF-β signaling (Bedossa et al., 
1995).  
3.2. Activins and Inhibins 
 
Inhibins and activins are non steroidal dimeric polypeptide hormones (Groome et al., 
1993). Gonadal activins play an important role in the production of the structurally 
unrelated pituitary follicle stimulating hormone FSH and as discoveries meticulously 
demonstrated also in the maintenance of bone mass and strength (Perrien et al., 
2007). Activins were first described as inducers of FSH secretion, the designation 
“activin” stems from this activity (Harrison et al., 2004). Later multiple other 
processes were linked to activins, which are structurally related to each other 
(Woodruff, 1998). In contrast, 1932 another isolated hormone demonstrated 
suppressing effects on FSH secretion of the anterior pituitary and was designated 
inhibin (McCullagh, 1932). Inhibins share the β subunits (see below) with activins, 
but lead to altered activities, when compared with activins (Kingsley, 1994). Previous 
research results on the expression pattern of activins demonstrate that βA and βB 
subunits were expressed in almost all tissues, especially in reproductive organs 
(Vejda et al., 2002). βC and βE expression is especially prominent in the liver, but also 
occurs at lower levels in a limited number of additional organs (Fang et al., 1997; 
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Hashimoto et al., 2002; Vejda et al., 2002).  High inhibin α mRNA amounts were only 
detected in adrenal and gonads (Phillips et al., 2009). 
 
 
3.2.1.  Activins - Structure and synthesis 
 
Activins, pluripotent growth factors, which originally were known as reproductive 
factors, can appear as homo- or heterodimers (Wharton et al., 2009)  (Figure 2) made 
up of four different β subunits in mammals (βA, βB, βC, βE), each encoded by its 
own gene (INHBA, INHBB, INHBC, INHBE). Many possible combinations of homo- 
(activins A, B, C, E) or heterodimers (AB, AC, AE, BC) can be formed but it is still 
unclear, how many combinations are actually formed in the body (Kreidl et al., 2009; 
Wada et al., 2005). There is the opportunity to form activins by dimerization of two β 
subunits or alternatively, inhibins can be formed by dimerization between one β and 
one α subunit (Ling et al., 1986). The most common forms are Activin A, B and AB. 
Additionally, activin βD has been described so far only in Xenopus laevis (Oda et al., 
1995) and might play a role in embryogenesis due to axis formative and mesoderm 
inductive qualities (O'Bryan et al., 2000; Oda et al., 1995). As with other members of 
the TGF-β family, the same structure with nine conserved cysteines in the mature 
peptides can be observed in the activin β subunit (Hashimoto et al., 2002). The sixth 
is used for dimerization, the other eight cysteines are necessary to form 
intramolecular disulfide bonds, which determine the folding of the peptides 
(Hashimoto et al., 2002). Activins are secreted as dimers of the mature peptides and 
no additional processing is necessary in the extracellular space to achieve bioactivity 
(Mason, 1994). The entire open reading frames of the β subunits of activins encode 
for precursors with 350-460 amino acids (aa), which weigh between 38 and 50 kDa 
(Grusch et al., 2008). The NH2 terminus bears a signal sequence which gives rise to a 
peptide of 19 hydrophobic amino acids and additional cleavage at a pentabasic 
cleavage site – aa 232 – 236 - in the ER and in the early Golgi releases the mature 
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carboxy –terminal peptides with either 115 or 116 aa (Hashimoto et al., 2002; 
Kingsley, 1994) (Figure 3). Also the activin βE subunit has a signal sequence typical 
for secretion as well as a potential cleavage site indicating its synthesis as a large 
precursor and subsequent processing. Phylogenetically on the one hand βA and βB 
can be grouped together and on the other hand βC and βE (Rodgarkia-Dara et al., 
2006). The latter two are encoded by closely linked (with respect to chromosome 
position) genes and most likely developed through tandem duplication (Fang et al., 
1997). 
 
 
 
 
 
 
 
 
 
 
Figure 2: Dimer formation of activins and inhibins: activins are made up of two β 
subunits; inhibins are formed by dimerization between one β and one α subunit. 
Adapted from (Phillips et al., 2009). 
Figure 3: Dimer formation of activin: the dimerized propeptide is 
enzymatically cleaved to produce the mature peptide (Phillips et al., 2009). 
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3.2.2. Activins - Signaling 
 
Activins A, B and the heterodimer AB initiate their biological activity, like most 
members of the TGF-β superfamily, through type I and type II transmembrane 
serine/threonine kinase receptors whereof various forms exist (Attisano et al., 1996; 
Pangas et al., 2000). Activin A, the signal transduction of which is best characterized, 
binds at first a type II receptor, whereof two types were identified ActR-II (A) and 
ActR-IIB (Abe et al., 2004; Pangas et al., 2000). This binding results in recruitment and 
phosphorylation of the type I receptor (Attisano et al., 1996) For activin A as ligand, 
the main receptor is ALK 4 (Activin receptor-like kinase) also called ActR-IB or 
ACVR1B (Tsuchida et al., 2004). Activins B and AB prefer to signal via ALK7 as type 
I receptor (Tsuchida et al., 2004). Receptors activated by activin C have not been 
detected so far. One study demonstrated that activin C was not in a competition with 
activin A for binding of the receptor (Wada et al., 2004) and chimeric activin 
containing the receptor binding sequence of βC instead of βA caused indeed type II 
receptor binding but did not have the ability to recruit ALK 4 (Muenster et al., 2005).  
The phosphorylated and activated receptors interact and activate downstream 
signaling effectors, SMADs, which in turn translocate into the nucleus and regulate 
transcription (Abe et al., 2004). A distinction is drawn between receptor SMADs (R-
SMADs: 1, 2, 3, 5, 8), common mediator SMADs (Co-SMAD 4) and SMADs with 
inhibitory function (SMADs 6 and 7). Which SMAD molecules get recruited, depends 
on the activated receptor (Figure 4). BMP signaling leads to SMAD 1, 5 and 8 
recruitment and activin A and TGF-β receptors have SMADs 2 and 3 as downstream 
effectors (Heldin et al., 1997; Wharton et al., 2009; Zhang et al., 2004). In spite of this, 
it has to be kept in mind that SMAD signaling cross talks with other signaling 
pathways (Wharton et al., 2009). Signal transduction by activin A for instance 
involves also SMAD-independent pathways like MAP-Kinase and Akt cascades, 
JNK, RhoA, p38 and MEKK1. There is substantial evidence that activin signaling 
underlies a tight regulation on the one hand by antagonists of activin signaling, on 
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the other hand production of activin subunits at the transcriptional or translational 
level is temporarily and spatially controlled. The glycoprotein follistatin (Fst) which 
is especially expressed in activin expressing organs, binds mature activin A (Tuuri et 
al., 1994) with high affinity (Kd 50-680 pM) (Harrington et al., 2006; Schneyer et al., 
1994; Sugino et al., 1993), which annuls activin A receptor association and thus signal 
transduction (de Winter et al., 1996). Besides activin A, early studies show that 
follistatin binds also to activin E (Hashimoto et al., 2002). To go into detail of Fst 
action, one activin dimer is clenched by two Fst molecules thus hiding its important 
parts for receptor binding and other residues (Thompson et al., 2005). Activins A, B, 
AB, E, and additionally other TGF-β family members such as myostatin, or several 
BMPs can all act as binding partners for follistatin or follistatin-like 3, which is 
related to follistatin and shares a similar ability in activin binding (Tsuchida et al., 
2000). Receptor binding by various TGF-β superfamily members is not very 
exclusive. Quite a few of the BMPs and myostatin all signal via ActR-IIB 
(Rebbapragada et al., 2003). Inhibins use their β subunits to bind type II receptors 
and additionally they can form a complex with TGFβ type III receptor, also 
designated betaglycan (Lewis et al., 2000). Due to the fact that the α subunit of 
inhibin is not capable to bind type I receptors activin signaling is repressed (Cook et 
al., 2004; Lewis et al., 2000).  
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3.2.3.  Activins - Function 
 
Activin signals have essential roles in a wide range of biological processes in 
different tissues and as consequence their deregulation can lead to tumor 
development, which is well documented by different research groups. In 
reproductive and endocrine organs activins demonstrated relation to tumorigenesis 
(Risbridger et al., 2001). In many processes like mesoderm induction, erythroid 
differentiation (Yu et al., 1987), gonadal functions, somatostatin expression 
(Sekiyama et al., 2009) stem cell biology, inflammation, reproductive biology, cell 
Figure 4: TGF-β superfamily ligands, receptor isoforms and corresponding 
downstream effector SMADs (downloaded from: http://www.biologie.uni-
regensburg.de/Biochemie/Deutzmann/Signal_WS/TGF_SigTrans_web.pdf; 
accessed 2011-06-29). 
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death induction, fibrosis and wound healing activins are found to be involved as 
important regulators (Chen et al., 2006) and the list is still not complete.  
Activin A, also functionally the best characterized member of the activin cytokines, 
arrests growth of prostate gland cells, adrenal gland cells, liver cells and mammary 
gland cells (Liu et al., 1996; Spencer et al., 1990; Wang et al., 1996; Zauberman et al., 
1997) and is involved in regulation of hippocampal long term potentiation (Shoji-
Kasai et al., 2007). Additionally, activin A stimulates cell growth of fibroblasts, 
osteoblasts and keratinocytes (Chen, Lui et al. 2002). In neuronal cells activins A and 
B behave as survival factors (Kupershmidt, Amit et al. 2007). Due to the expression of 
activin A by various immune cell types during inflammatory processes, mediator 
functions in immune responses count to the widespread actions of activin A (Ebert et 
al., 2007; Eramaa et al., 1992; Phillips et al., 2009; Scutera et al., 2008).  
Cripto, which is implicated in the TGF-β signaling pathway, has been shown to 
inhibit activin signaling and to be highly overexpressed in breast cancer, a cancer cell 
model, which has low levels of activin and its receptors by down regulation (Liu et 
al., 1996). Another activin antagonist, follistatin-like 3 also called follistatin–related 
gene (FLRG) has high expression levels in breast cancer compared to healthy tissue 
and silencing of FLRG expression inhibits breast tumor growth and at the same time 
restores responsiveness to activin A (Razanajaona et al., 2007). In melanoma cell lines 
and liver cancer follistatin is detectable at high levels and at the same time the 
responsiveness to activin is reduced (Rossmanith et al., 2002; Stove et al., 2004). 
Follistatin was able to suppress metastasis formation in small cell lung cancer cells 
(Ogino et al., 2008) and was shown to be involved in v-src connected oncogenic 
transformation of fibroblasts in chicken embryos (Masker et al., 2007) and in gastric 
cancer (Kang et al., 2008). Although activin A up-regulation is found in many tumor 
models, it is not a general observation. Thus the pro- or antitumorigenic character of 
activin A depends on the cancer tissue type and activins and their antagonists are 
closely connected to tumor development in several organs. Activin βA knock-out 
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mice showed craniofacial defects and postnatal lethality. Activin βB knock-out mice 
had defects in female reproduction and the development of eyelids was disturbed 
(Schrewe et al., 1994; Vassalli et al., 1994). 
Activin C, which acts as an opponent of activin A is increased in testis, prostate and 
liver tumors (Gold et al., 2009). Activin C overexpressing transgenic mice 
demonstrated infertility, enlarged livers and prostate diseases with decreased 
SMAD2 levels in the affected organs, indicating inhibition of activin A signaling in 
vivo (Gold et al., 2009). Mice lacking activin βC or βE developed normally and the 
liver was not malfunctioning (Lau et al., 2000). Since βC expression is high in the 
liver, activin βC might act as a regulator of hepatic activin βA levels (Butler et al., 
2005). Briefly, in vitro βC overexpression  induced contradictory consequences in 
growth of different cell lines (Butler et al., 2005; Mellor et al., 2003; Mellor et al., 2000; 
Vejda et al., 2003; Wada et al., 2004) which is not surprising considering the fact that 
contradictory effects on growth were also demonstrated for other TGF-β members.  
 
3.3. Activin βE – Signaling and Function 
 
Activin βE, was the latest activin subunit to be discovered and filed into the activin 
branch of the TGF-β superfamily, of which the common roles have yet to be defined 
(Figure 5). It was first described and detected in the mouse (Fang et al., 1996), 
followed by identification of orthologs in rat (O'Bryan et al., 2000) and human 
(Hashimoto et al., 2002). In addition to homodimeric activin E, previous studies 
suggest that the βE subunit can also form the heterodimers CE and AE (Vejda et al., 
2002). The formation of inhibin E (α:βE) and activin BE has not been demonstrated so 
far. 
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Activin βE signaling mechanisms have not been identified till now. Previous 
discoveries suggest that activin E does not signal via activin A receptors in contrast 
to activin A (Emanuel Kreidl, Diploma Thesis at the University of Vienna, 2008). 
Furthermore activin E does not block activin A signaling (Emanuel Kreidl, Diploma 
Thesis at the University of Vienna, 2008). In the course of investigating the signaling 
mechanisms of activin βE, conditioned media from cells with high transient 
expression of activin βE did not activate SMAD2 phosphorylation in HepG2 cells and 
VM48 melanoma cells. Studies demonstrated that βC expression in cells co-
expressing other activin subunits including βA lead to more heterodimerization and 
less homodimeric activin A and thus alterations in induction of signal transduction 
(Mellor et al., 2003). Similar mechanisms might also apply to activin βE. In addition, 
activin βE is a target for RASSF1A, a tumor suppressor which is often epigenetically 
silenced in several tumor entities and which leads to decreased cell proliferation after 
reexpression in cancerous cells (Chow et al., 2006). Overexpression of RASSF1A led 
to activin βE expression stimulation, whereas RASSF1A knockdown led to INHBE 
down regulation (Chow et al., 2006). Chow, Lam et al. 2006 demonstrated also that 
Figure 5: Synthesis of activin E and dimerization 
possibilities with other activin subunits. (Emanuel Kreidl, 
Diploma Thesis at the University of Vienna, 2008). 
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Inhibitor of DNA binding 2 (Id2), a potential oncogene which is known as a TGF-β 
target (Lasorella et al., 2001), was downregulated when activin βE levels were 
elevated. Also in case of activin βE a crosstalk with different signaling pathways has 
to be considered, due to the fact that the INHBE gene was e.g. a reported target for 
hedgehog signaling (Katoh et al., 2008). In connection with activin βE regulation, 
important transcription factor SP1 binding sites for basal activin βE expression were 
identified in previous studies of our group (Alev Deli, Diploma Thesis at the 
University of Vienna, 2008). Besides, Trichostatin A and sodium butyrate were found 
to act as potent inducers of activin βE, whereas dexamethasone and interferon (IFN) 
gamma prevented the expression of activin βE.  
 
The screening of activin appearance in many tumor entities led to the observation 
that in multiple leukemia cell lines activin βE is highly expressed, most notably in the 
K562 CML leukemia cell line (Rodgarkia-Dara personal communication and 
manuscript in preparation).  Screening of human peripheral blood mononuclear and 
healthy bone marrow cells revealed that βE was nearly undetectable in bone marrow, 
whereas elevated levels of βE were found in leukemia cell lines.  
Investigation of βE expression indicated main expression in hepatocytes and 
decreased expression levels in multiple hepatoma cell lines (Vejda et al., 2002; Vejda 
et al., 2003). After liver damage activin βE mRNA was upregulated and in 
hepatocellular carcinoma (HCC) βE is downregulated. At this point it has to be 
mentioned that activin A is contrarily expressed in case of liver damage, where its 
mRNA levels are decreased (Deli et al., 2008). Observation of developing mouse liver 
revealed the interesting fact that activin βE was undetectable until very late 
embryonic development stages and the peak was at birth  (Lau et al., 2000). Previous 
data of our research group from a study focusing on the relationship between activin 
expression and feeding conditions of rats demonstrated noticeable changes in activin 
βA and βE expression whereas βC mRNA levels hardly changed. Fasting led to 
higher activin βE and βC mRNA levels and lower activin βA levels in fed controls 
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(Rodgarkia-Dara et al., 2006).  Several studies show that activin βE is abundantly 
expressed in hepatocytes, whereas it is reduced in dedifferentiated hepatoma cells.  
Overexpression of activin βE in rat AML12 cells and human hepatoma cell lines 
HepG2 and Hep3B induced apoptosis through caspases and reduced proliferation 
rates (Vejda et al., 2003; Wada et al., 2005). Furthermore in cultured hepatocytes, in 
exocrine pancreas by inhibiting acinar cell growth (Osamu Hashimoto) and in mouse 
liver cells the pro-apoptotic behavior of activin βE was observed indicating a role in 
regulation of cell number (Chabicovsky et al., 2003; Hashimoto et al., 2002; Wada et 
al., 2005). Nevertheless, it is still an open question, how activin βE exerts this effect 
and which signaling receptors are involved. Transient overexpression of activin βE 
also led to inhibition of DNA synthesis (Chabicovsky et al., 2003). In connection with 
hypoxia, gene chip analysis illustrated changed INHBE mRNA levels in HepG2 cells 
(Fisher et al., 2005). INHBE gene mutation is additionally observed in human breast 
and colorectal cancer (Sjoblom et al., 2006). Lau et al. demonstrated that mutant mice 
lacking βE expression grew normally and had no abnormalities compared to wild-
type mice. After partial hepatectomy the liver regenerated as in non-mutant mice, 
questioning an essential role of activin βE in liver growth regulation. This 
consideration is confirmed by βE overexpressing transgenic mouse studies, where 
neither macroscopic nor microscopic liver aberrations emerged (Hashimoto et al., 
2006). Studies focusing on the inflammation-stimulating behavior of activin βE 
illustrated significantly increased levels of βE after injection of lipopolysaccharide 
(LPS) into rats (O'Bryan et al., 2000). Activin βE expression seems to be fine tuned in 
many regulatory processes, as applies to all activins. Induction of osteogenic 
differentiation in human mesenchymal cells led to strongly elevated INHBE 
expression together with TGF-β1 and TGF-β2 increase (Martin et al., 2010). Sekiyama 
et al. used βE overexpressing transgenic mice for behavior research and concluded, 
that male and female activin βE overexpressing mice had less anxiety and more 
combativeness. Subsequently, stress resistance differences in wild-type and βE 
overexpressing mice were investigated. The number of c-Fos positive cells in the 
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hypothalamic paraventricular nucleus (PVN) was reduced in transgenic mice as it is 
in response to acute stress, indicating an activin βE influence on the hypothalamic-
pituitary-adrenal axis (Sekiyama et al., 2009). Endoplasmic reticulum (ER) stress 
triggered e.g. by protein load of unfolded or misfolded proteins necessitates ER 
differentiation. Dombroski et al. investigated gene expression after ER stress 
induction in human B cells and registered INHBE and very low density lipoprotein 
receptor (VLDLR) augmentation. Subsequent expression analysis after ER stress in 
human fibroblasts with likewise results confirmed the previous observations 
(Dombroski et al., 2010).  
In the course of assessing possible functions of activin βE in glucose metabolism in 
liver cells, more precisely the effects of insulin on activin βE, Hashimoto et al. noticed 
stimulatory effects of insulin on βE expression (Hashimoto et al., 2009). These 
observations differ from previous studies, which illustrated higher activin βE levels 
in fasting mice (Rodgarkia-Dara et al., 2006), where insulin levels could be expected 
to be decreased. Such findings suggest a complex regulation of activin βE and 
highlight the necessity of more knowledge about this cytokine. Hashimoto et al 
suggested that these converse observations indicate that not only insulin but also 
other factors control activin βE expression and synthesis. Interestingly, Brown et al. 
demonstrated that combined loss of follistatin and follistatin-like 3 in mice resulted 
in augmentation of body fat and resistance to insulin in spite of more insulin 
synthesis (Brown et al., 2011).  
As described above reproductive functions are one of the most prominent 
involvements of activins. Mylonas et al. investigated the evidence of activin E in 
human endometrial tissue and arrived at the conclusion that the presence of activin E 
in human endometrium might have important functions for endometrial maturation 
and the implantation of blastocyst (Mylonas et al., 2010). 
These observations underline the importance to elucidate the biological functions of 
the gene products of INHBE in mammalian physiology and the investigation of their 
signaling mechanisms.  
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3.4. vβE - an alternative transcript 
 
In the course of βE analysis an alternative transcript was found to be expressed from 
the gene encoding βE and was termed vβE. This transcript gives rise to a protein of 
unknown function lacking a signal peptide and consequently localized to the 
cytoplasm and nucleus. (Alev Deli, Diploma Thesis at the University of Vienna, 
2008). For none of the other activins similar alternative transcripts have been 
described so far. A chimeric vβE and yellow fluorescent protein transfected in 
hepatoma cell lines indicated localization to the nucleus and cytosol and stable clones 
from these cells tended to lose expression of vβE by and by. It is strongly suggested 
that vβE has completely unrelated functions to activins (Alev Deli, Diploma Thesis at 
the University of Vienna, 2008) which, however, have not been defined yet. 
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3.5. Aim: Elucidation of activin beta E functions and 
signaling mechanisms 
 
Due to the fact that activin βE may contribute to malignant growth, the central aim of 
this diploma thesis was to clarify, how activin βE affects malignant cells and its 
signaling mechanisms which have still to be identified. Thus, we used a dual 
approach, where, on the one hand we carried out a knockdown of activin βE in high 
endogenous activin E expressing cell lines K562 and HepG2. On the other hand we 
constructed expression vectors for stable overexpression of activin βE and vβE in 
Hep3B cells with low βE levels, and in HepG2 cells.  For phenotypical 
characterization of activin E function, several in vitro assays were carried out with 
stable clones generated from these cell lines. Subsequently, to find potential 
pathways in which activin E is involved, transcriptome analyses were carried out 
using genome wide expression arrays with the generated subclones with elevated or 
decreased activin βE levels.  Additionally, a baculovirus expression system was used 
for production of recombinant activin E. Due to the fact that vβe expression gets 
gradually lost after transfection, a tetracycline- inducible gene expression system was 
implemented for overexpression analysis in hepatoma cells.  
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4. Materials and Methods 
 
4.1. Molecular Cloning 
 
4.1.1. Gel electrophoresis 
 
DNA fragments were separated or analyzed by agarose gel electrophoresis 
consisting of respectively 1 or 2 % (w/v) agarose (StarLab) in 0.5 x TBE buffer (5.4 g/l 
tris (Fluka) 2.75 g/l boric acid (Sigma), 1 mM EDTA). Samples were mixed with 
Vistra-Green loading dye (0.5 μl/ml 10 000 x Vistra-Green (GE Healthcare), 333 μl/ml 
6 x loading dye (Fermentas), 66.5 μl/ml 0.5 M EDTA, 250 μl/ml 80% glycerol (Merck)) 
prior to loading onto the gel. GeneRuler 1 kb DNA Ladder (Fermentas) was used as 
marker to determine the length of fragments. The gel was run in 0.5 x TBE at a 
voltage of 55 V for 10 minutes (min) followed by an increase to 90 V until the bands 
were separated properly (power supply: Bio-Rad).  
 
4.1.2. RT-PCR 
 
Control PCRs were performed using Taq Polymerase and all steps were conducted 
on ice. The PCR reactions contained 17.375 μl nuclease-free H2O, 5 μl of 5 x PCR 
buffer, 0.5 μl of dNTP mixture (10 mM), 0.5 μl of 5´primer (0.4 pmol), 0.5 μl of 
3´primer (0.4 pmol), 0.125 μl of GoTaq- DNA polymerase (1.25 units, Fermentas) and 
1 μl template DNA. All PCR amplifications were carried out with a protocol of 
denaturation at 95°C for 2 min, followed by annealing at 50°C for 50 s, and 
polymerization at 72°C for 1 min, for 30 cycles in a DNA thermal cycler (Biorad). 
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Pfu- PCR was used to produce insert DNA for vector constructs, due to the 
proofreading capability of Pfu-Polymerase. The PCR reactions contained 40.5 μl 
nuclease-free H2O, 5 μl of 10 x PCR buffer with MgSO4, 1 μl of dNTP mixture (10 
mM), 1 μl of 5´primer (0.4 pmol), 1 μl of 3´ primer (0.4 pmol) and 0.5 μl of Pfu DNA 
polymerase (Fermentas) and 1 μl template. All PCR amplifications were carried out 
with a protocol of denaturation at 95°C for 2 min, followed by annealing at 50°C for 2 
min, and polymerization at 72°C for 1 min, for 30 cycles in a DNA thermal cycler. 
Colony PCR was used to analyze if bacmid constructs contained the insert of 
interest. The following approach has been used: 5 μl 10 x Buffer with MgSO4, 1 μl 
dNTPs (10 mM), 0.5 μl Pfu-Polymerase, and 40.5 μl nuclease-free H2O. A colony was 
picked from the plate and diluted in 1 x PBS, whereof 1 μl was used as template for 
PCR. Above all 1μl upstream primer (0.4 pmol) and 1 μl downstream primer (0.4 
pmol) were added to every reaction, spinned down and placed into the thermocycler 
(40 cycles, 30 sec 95°C, annealing: 2 min 50°C , elongation: 2 min 70°C). DNA was 
stored at 4°C.  
Primers used for RT-PCR procedures are shown in table 1.  
Table 1: Primers used for molecular cloning 
Primersequences  Comments 
5´CCCGAATTCCGCCATGCTAGAAATAAAGAGACCAGA- 
3´  
Forward primer for amplification of human vβE, 
adding an EcoRI restriction site upstream of the 
ATG. 
5´TTTGGATCCTAGCTGCAGCCACAGGCCTC-3´ Reverse primer for amplification of hvβE with stop 
codon and adding a BamHI restriction site. 
5´CATCATCATCATCATCATTTGGAGTGTGATGGCAAGG-
3´ 
His_Tag_AbetaA_mat: forward primer for mature 
form of His_INHBA 
5´GTCGTCGTCGAATTCCAGGATGCCCTTGCTTTGGCTGA
G-3´ 
HsActivinbetaA_for: forward primer for proform of 
INHBA_His 
5´ATGATGATGAGGCCTTGGGCTGGGCAACTCTATG-3´ HsActivinbetaA_rev: reverse primer for mature 
form of His_INHBA 
5´ATGATGATGATGATGATGGCCCCGCCGACGCCGGCGA
T-3´ 
pro_betaA_His_rev: reverse primer for proform of 
INHBA_His 
5´CATCATCATCATCATCATCCCACCTGTGAGCCTGCGA-
3´ 
His ACTE mature: forward primer for mature form 
of His_INHBE 
5´TATAAGCTTTAGCTGCAGCCACAGGCCTC-3´ ACTE mit stop HindIII: reverse primer for mature 
form of His_INHBE 
5´ATGATGATGATGATGATGGGTCCTCCTCCTGGCCCGGC
-3´ 
pro His ACTE rev: reverse primer for proform of 
His_INHBE 
5´TTTGAATTCCAGGAGCATGCGGCTCCCTGA-3´ HsβE for around ATG with EcoRI 
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4.1.3. Dephosphorylation of the vector backbone 
 
Calf intestinal alkaline phosphatase (CIAP: 1u/μg DNA, Fermentas) was used for 
dephosphorylation of the target vector according to the manufacturer’s instructions.  
For the dephosphorylation procedure 1 μl CIAP was added to the restriction mix and 
incubated for 30 min at 37°C. Since CIAP works in almost all Fermentas buffers there 
was no need to change the buffer. Then again 1 μl CIAP was added and incubated 
for 30 min at 37°C. For inactivation of CIAP enzyme the digest mixture was 
incubated at 75°C for 10 min.  
 
4.1.4. DNA concentration measurement 
 
To determine the concentration of plasmid DNA from the respective positive clone, a 
nanodrop (Nanodrop 1000) measurement was performed. To initialize the 
instrument, 1 μl ddH2O was loaded on the sample valve. Again 1 μl ddH2O was 
loaded and measured for null-adjustment; subsequently 1 μl of the plasmid sample 
was loaded and OD260 measured. 
 
4.1.5. Restriction digests 
 
For diagnostic restriction digests 1 μl plasmid-DNA diluted in 7.5 μl depc H2O 
(diethylpyrocarbonate-treated H2O) was mixed with 1 μl of the respective buffer 
(Fermentas) and digested with 0.5 μl restriction enzyme (10 u/μl, Fermentas). The 
restriction mixture was incubated at 37°C for 1-2 hours on the thermoblock.  For 
preparative digests 2-10 μg of plasmid-DNA were restricted with 10-25 units of 
respective restriction enzymes over night. Buffers and double digest conditions were 
used as recommended by Fermentas. For partial digests 2 μg DNA with 5 units of 
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restriction enzyme were prepared in a 50 μl restriction approach and after 5, 10, 20, 
40 and 50 min of incubation time 10 μl aliquots were mixed with Vistra-Green 
loading dye and stored at -20°C for further gel electrophoretic analysis. Klenow 
Polymerase (Fermentas) was used to generate blunt ends for further blunt end 
ligation according to the manufacturer´s protocol.  
 
4.1.6. DNA purification 
 
For purification of PCR products or restricted DNA fragments, or to change the 
buffer of PCR products the Promega Wizard SV Gel and PCR Clean-Up System was 
used according to the instructions of the manufacturer. DNA fragments or PCR 
products were loaded on a preparative agarose gel and after separation via gel 
electrophoresis the desired fragments were excised from the gel. The slices were 
weighed to add subsequently 1 μl membrane binding solution per 1 mg gel and to 
dissolve the mixture through incubation at 65°C. The completely dissolved DNA was 
transferred to an SV minicolumn which was inserted into a collection tube. The tube 
was incubated 2´ at room temperature (RT) and centrifuged at 16 000 g for 1 min 
(Eppendorf Centrifuge 5417R). The flow-through was discarded and the column 
reinserted into the collection tube. Subsequently 700 μl membrane wash solution were 
added to the minicolumn and centrifuged likewise. The flow-through was removed 
and the column was washed again with 500 μl membrane wash solution. To eliminate 
excess of washing reagent another centrifugation step was performed at 16 000 g for 
1 min with the empty assembly. Then the minicolumn was transferred to a 1.5 ml 
tube (Eppendorf), 50-100 μl nuclease-free water were added directly onto the column 
and incubated for 2 min. DNA was eluted by recentrifugation (16 000 g, 1 min), the 
column discarded and the DNA containing flow-through was stored at -20°C.  
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Membrane binding solution: 
 
 4.5 M  guanidine isothiocyanate 
 0.5 M  potassium acetate (pH 5.0) 
 
 
Membrane wash solution 
 10 mM potassium acetate (pH 5.0) 
 80%  Ethanol 
 16.7 µM EDTA (pH 8.0) 
 
4.1.7. Ligation 
 
Ligation procedures were performed in 10 μl total volumes over night (o/n) at 16°C 
or 5-10 min at 25°C for rapid ligation. Insert DNA was in molar excess to the vector 
(60-100 ng) in a ratio of 3:1 or 4:1. Briefly, the ligation approach contained insert 
DNA, vector DNA, 1 μl 10 x T4 DNA ligase buffer (Fermentas) or 2 μl 5 x rapid 
ligation buffer (Fermentas) for rapid ligation, 1 μl T4 DNA ligase (5 u/ μl, 
Fermentas). The mix was then filled up to 10 μl with nuclease-free H2O. As control 
for religation a sample was prepared containing nuclease-free H2O instead of insert 
DNA. 
 
4.1.8. Transformation 
 
Heat Shock transformation protocol for JM109 E.coli  
For the transformation procedure competent E.coli strains were thawn on ice. In a 
tube (Eppendorf) 3 μl ligation mix were mixed with 70-100 μl of competent cells  
(JM109 E.coli-strain) and stored on ice for 20 min; followed by a heat shock of exactly 
1 min at 42°C and by a quick addition of 1 ml SOC Medium (Yeast extract 0.5% (w/v), 
trypton 2% (w/v), sodium chloride 10 mM, potassium chloride 2.5 mM, magnesium 
chloride 10 mM, glucose 20mM, pH 7). Subsequently bacteria were rotated for 1-2 
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hours (h) at 37°C on a shaking thermoblock and then plated on LB plates (for plates 
15 g agar/l LB medium were added) containing the desired antibiotic. The plates 
were incubated at 37°C over night (Heraeus incubator). 
 
Heat Shock transformation protocol for DH10Bac E.coli  
For the transformation procedure competent E.coli strains were thawn on ice. 4 μl of 
ligation solution were mixed with 75 μl of competent DH10Bac E.coli cells and placed 
on ice for 20 min followed by a heat shock (42°C, 1 min) and addition of 1 ml SOC 
medium. Subsequently bacteria were rotated for 1-2 hours at 37°C on a shaking 
thermoblock and then plated on LB plates containing the desired antibiotic or 
additive (Table 2). The plates were incubated at 37°C over night (Heraeus incubator). 
After 48h blue and white colonies were visible. 
SOB Medium (for 1 liter) 
 
20 g  trypton 
5 g  yeast extract 
0.5 g  NaCl 
+10 ml  250 mM KCl 
pH was set to 7 with NaOH and the medium autoclaved 
SOC Medium  
 
SOB Medium + 1/100 Vol. autoclaved 1 M MgCl2-solution (10 mM MgCl2) 
   + 1/100 Vol. autoclaved 2 M glucose-solution (20 mM glucose) 
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Table 2: Additives for growth medium 
 Additives Final concentration in growth medium 
Ampicillin (Roche) 50 μg/ml 
Kanamycin (Fluka) 50 μg/ml 
Gentamicin (Sigma) 7 μg/ml 
X-gal (Fluka) 100 μg/ml 
Tetracyclin (Sigma) 10 μg/ml 
IPTG 40 μg/ml 
 
 
4.1.9. Quick and Dirty Miniprep 
 
“Quick ‘n’ Dirty” plasmid isolation of overnight cultures: 
To screen for potential positive clones, tubes (Falcon) containing 1.5 ml LB  (10 g 
peptone, 5 g yeast extract, 5 g NaCl, in 1 l H2O, pH 7.0) and the appropriate antibiotic 
(Table 2) were inoculated with single colonies and incubated on a 37°C shaker at 200 
revolutions per minute (rpm) over night. Subsequently a plasmid“quick- mini 
preparation” was performed from overnight cultures for further control restrictions 
of plasmids containing the gene of interest. Cells were harvested and dissolved in 
700 μl STET buffer (50 mM Tris, 50 mM EDTA, 8% Sucrose, 5% Triton-X). After 
adding 13 μl lysozyme (10 mg/ml) to each sample, they were inverted and boiled at 
100°C for 2 min. With another centrifugation step cell debris, proteins and 
chromosomal DNA were pelleted and removed with a RNase A-covered toothpick. 
Plasmid DNA was precipitated with 700 μl isopropanol which were added to the 
remaining supernatant and the samples were stored at -20°C for 20 min. 
Subsequently the DNA was pelleted, washed once with 70% ethanol and the pellet 
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was air dried. The extracted plasmid DNA was resuspended in 15 μl TE-buffer (100 
mM Tris, 10 mM EDTA, pH 8) and stored at -20°C. 
STET- buffer (500 ml, pH 8) 
 
25 ml   1 M Tris/HCl [50 mM Tris] 
50 ml   0.5 M EDTA [50 mM EDTA] 
40 g  Sucrose 
+ bidest. H2O to 475 ml and then autoclave 
+ 25 ml Triton X 
 
Alkaline lysis Miniprep for bacmids (DH10 E.coli strain) 
1.5 ml of an overnight culture were pelleted (14 000 g, 1 min) and after aspirating the 
supernatant the cells were gently resuspended in solution I (15 mM Tris-HCl pH 8.0, 
10 mM EDTA, 100 μg/ml RNAse A, filter-sterilized and stored at 4°C). 0.3 ml of 
Solution II (0.2 N NaOH, 1% sodium dodecyl sulphate (SDS), filter-sterilized) was 
added afterwards and incubated for 5 min at RT. 0.3 ml 3 M potassium acetate was 
added to the now nearly translucent lysate, mixed gently and placed on ice for 5-10 
min. Then the mixture was centrifuged (15 min, 14 000 g, -20°C), the supernatant 
transferred to a tube containing 0.8 ml isopropanol, inverted a few times and then 
placed on ice for 10 min. The sample was centrifuged again (14 000 g, 15 min) and the 
supernatant carefully removed. 0.5 ml of 70% ethanol was added to wash the pellet, 
the tube was centrifuged again (14 000 g, 5 min) and the supernatant discarded. 
Finally the DNA containing pellet was dissolved in 40 μl 1 x TE Buffer and stored at 
4°C. 
4.1.10. Plasmid Isolation: Miniprep 
 
Wizard Plus SV Minipreps DNA Purification System (Promega) was used to obtain 
“pure” plasmid DNA from transformants. 1.5 ml of bacterial o/n culture was 
centrifuged (16 000 g, 5 min) and after aspiration of the supernatant the remaining 
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pellet was resuspended in 250 μl cell resuspension solution. Then 250 μl cell lysis 
solution were added, the tube was inverted 4 times and incubated for 3 min at RT. 
Next 10 μl of alkaline protease solution was added to the lysate, inverted again 4 times 
and the incubation repeated for 5 min at room temperature. Subsequently 350 μl 
neutralization solution were added to the mix and centrifuged at 16 000 g for 10 min. 
The cleared supernatant was transferred to a spin column which had been inserted 
into a collection tube. The lysate was incubated for 2 min and centrifuged at 16 000 g 
for 1 min. The flow-through was discarded and 750 μl wash solution was pipetted 
onto the column, which was recentrifuged at 16 000g for 1 min. The flow-through 
was discarded again. The same step was repeated with 250 μl of wash solution. DNA 
was eluted in 100 μl nuclease-free water, which was passed through by 
centrifugation (16 000g, 1 min) after the spin column had been transferred to a sterile 
1.5 ml tube and incubated for 2 min. The eluted DNA was stored at -20°C. 
Cell Resuspension Solution  
 50 mM Tris-HCl (pH 7.5) 
 10 mM EDTA 
 100 μg/ml  RNase A 
 
Cell Lysis Solution 
 0.2 M  NaOH 
 1%  SDS 
 
Neutralization Solution (final pH 4.2) 
 4.09 M  guanidine hydrochloride 
 0.75 M  potassium acetate 
 2.12 M glacial acetic acid 
 
Column wash solution 
 162.8 mM potassium acetate 
 22.6 mM Tris-HCl (pH 7.5) 
 0.109 mM EDTA (pH 8.0) 
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4.1.11. Plasmid Isolation: Midiprep 
 
The PureYield Plasmid Midiprep System (Promega) was used to perform midipreps and 
obtain pure plasmid DNA in high amounts. 100 ml of bacterial o/n cultures 
containing positive clones were harvested by centrifugation at 5 000 g for 10 min. The 
pellet was resuspended in 6 ml resuspension solution and afterwards lysed in 6 ml cell 
lysis solution by incubating for 3 min at RT. Subsequently 10 ml neutralization solution 
were added to the lysate and incubated again for 3 min. A clearing column was placed 
into a binding column and this assembly onto a vacuum manifold (Promega). The 
supernatant, which was gained after an additional centrifugation step at 15 000 g for 
10 min, was transferred to the clearing column and vacuum was applied till the 
supernatant had passed through each column. The clearing column was removed and 
discarded and 5 ml endotoxin removal wash and after that 20 ml column wash solution 
was passed through the binding column. Vacuum was applied 30-60 sec longer to 
remove remaining liquid. 600 μl of nuclease-free water were transferred onto the 
column and incubated for 5 min. Finally DNA was collected with the Eluator Vacuum 
Elution Device (Promega) by vacuum application and stored at -20°C. 
 
4.1.12. Preparation of glycerol stocks 
 
700 μl of a bacterial o/n culture were transferred to a 1.5 ml tube (Eppendorf) and 
mixed with 300 μl of 80% glycerol (autoclaved). Prepared glycerol stocks were stored 
at -80°C for long-term storage. 
 
4.1.13. DNA and RNA precipitation 
 
DNA precipitation was carried out as follows: DNA solution was mixed with 3 x 
volume (V) 100% EtOH (Merck) and 1/10 V 3M sodium acetate pH 5.2 (Merck) and 
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incubated over night at -20°C. The next day the mixture was centrifuged at 4°C at 20 
800 g for 15 min, the supernatant was discarded. The remaining pellet was washed 
with 500 μl 70% EtOH and centrifuged again at the same conditions but only for 5 
min. The supernatant was aspirated and the pellet air dried for 10-15 min. The 
precipitate was resuspended in TE buffer in a desired volume. 
 
4.1.14. Sequence analysis 
 
All purified and cloned vector constructs were verified by nucleotide sequencing of 
the amplified region (Mycrosynth laboratory, CH-9436 Balgach) using CMV forward 
and reverse primer. For that purpose 0.8 μg DNA were sent to the company. 
Sequencing results were received via e-mail and alignment with the corresponding 
sequences in the Refseq database was performed with Clone Manager software. 
 
 
4.2. Protein biochemistry 
 
4.2.1.  Protein precipitation from cell lysates  
 
Cell supernatant was centrifuged at 1 500 rpm for 10 min to remove dead cells and 
debris. 4 x V of 100% EtOH was added and the precipitate stored at -20°C for at least 
24 hours. Subsequently, the supernatant-ethanol mix was centrifuged (15 000 g, 10 
min, 4 °C), the pellet was resuspended in 1 ml 100% EtOH and transferred to a 1.5 ml 
tube. After recentrifugation at the same conditions but only for 5 min the cell pellet 
was air dried and then resuspended in a desired volume, dependent on the pellet 
size, in Lysis Buffer II (1 mM EGTA, 150 mM NaCl, 1 mM Na3VO4, 1% triton X, 10 
mM NaF, 50 mM Tris, complete tab (Roche)). Protein samples were stored at -20°C. 
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4.2.2. Protein isolation from whole cell extracts 
 
All steps were done on ice. Cells were scratched/scraped off into 1 ml 1 x PBS and 
pelleted (centrifugation at 1 000 rpm for 5 min). PBS was aspirated and the cell pellet 
lysed by resuspending in Lysis buffer II, the volume of which depended on cell 
amount. Prior to usage, the cell lysate was sonicated 2 times for 5 min. Insoluble 
components were removed after centrifugation at 4°C and 20 800 g for 10 min. The 
cleared supernatant was transferred to a new tube.  Protein samples were stored at -
20°C.  
 
4.2.3.  Determination of protein concentration 
 
Protein concentration was determined with Biorad Protein Assay Reagent. The 
protein samples were diluted 1:10 with cell Lysis buffer II. A standard curve, which 
had been obtained from bovine serum albumin (BSA) dilutions (0.1, 0.2, 0.4, 0.8, 1.0, 
1.2 mg/ml) was used to estimate total protein concentration. The assay was 
performed in a 96-well microtiter plate (Greiner) and Lysis buffer II served as blank. 
The pipetting scheme was performed according to tables 3 and 4. BSA dilutions and 
protein sample dilutions were mixed with 190 μl of dilution of the assay reagent (1: 5 
with water) and incubated for 10 min at RT. The absorption was measured then at 
595 nm using the SynergyHT plate reader (BioTEK) and concentrations determined 
with Gen5 software (BioTEK). 
Table 3: Pipetting scheme of Bradford assay for BSA standard curve 
 ddH2O 
(μl) 
Lysis Buffer 
(μl) 
BSA-Standard 
(1μg/μl) 
Bradford reagent 
(μl) 
Concentration 
(μg/μl) 
Blank 9  1 0 μl 190 0 
Standard 
1 
8  1 1 μl 190 0.1 
Standard 7  1 2 μl 190 0.2 
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2 
Standard 
3 
5  1 4 μl 190 0.4 
Standard 
4 
3  1 6 μl 190 0.6 
 
 
 
Table 4: Pipetting scheme of Bradford assay for protein samples 
 ddH2O (μl) Sample (μl) Bradford reagent (μl) 
Sample 9 1 190 
 
 
4.2.4.  SDS PAGE and Western Blot analysis  
 
SDS gel electrophoresis:  
10 or 12% (according to protein sizes to be investigated) discontinuous 
polyacrylamid (PAA) gels were prepared to separate isolated proteins (Table 5). 5 μl 
prestained marker (Page Ruler Plus Prestained Protein Ladder, Fermentas) was used 
to compare and estimate protein weights. Separating (10-12%) and stacking (5%) gels 
were mixed and prepared according to the table below and topped with isopropanol, 
which was removed after polymerization with filter paper. 40 μg of protein lysate 
were mixed with 5 x loading buffer (300 mM Tris/HCl pH 6.8, 60% glycerol, 10% 
SDS, 0.025% bromophenol blue, under denaturating conditions additionally 7% β-
mercaptoethanol), incubated at 100°C for 5 min for denaturation, and loaded onto 
the gel.  Gels were run starting with 55 V until separation of the marker and voltage 
was increased to 120 V for 2 hours in SDS running buffer (25 mM Tris, 192 mM 
glycin, 0.1% SDS).  
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Table 5: Preparation of separating and stacking gels: pipetting scheme 
10% Separating gel (10ml) 12% Separating gel (10ml) 5% Stacking gel 
3.92 ml distilled H2O 
 
3.25 ml distilled H2O 3.6 ml distilled H2O 
 
2.5 ml 1.6 M Tris-HCl, pH  8.8 
 
2.5 ml 1.6 M Tris-HCl, pH  8.8 0.625 ml 0.5 M Tris-HCl, pH 6.8 
 
 
 
3.35 ml 30% Acrylamid/Bis; 29:1 
(Bio-Rad) 
 
4.02 ml 30% Acrylamid/Bis; 29:1 
(Bio-Rad) 
0.625 ml 30% Acrylamid/Bis; 
29:1  
 
200 µl 20% SDS 
 
200 µl 20% SDS 100 µl 20% SDS 
 
25 µl 10% ammonium persulfate 
(APS, Merck) 
 
25 µl 10% ammonium persulfate 
(APS, Merck) 
50 µl 10% APS  
10 µl Temed (Amresco) 
 
10 µl Temed 
 
7.5 µl Temed  
 
Western Blotting 
Separated Proteins were blotted onto a polyvinylidenfluorid (PVDF) membrane, 
therefore the following assembly was generated: three filter papers were soaked in 
Towbin transfer buffer (25 mM Tris, 192 mM glycin, 5% MeOH) and placed at the 
bottom, the PVDF membrane (Hypond-P, GE Healthcare) which was previously 
activated in methanol, was arranged on the filters, the stacking gel was laid onto the 
membrane and the assembly was finished by additional three filter papers on the 
top. Air bubbels were removed and the assembly was placed into the electrotransfer 
unit, which was filled with transfer buffer. Transfer procedure was carried out with 
18 V at 4°C o/n or with 200 mA at 4°C for 2 hours. 
The membrane was washed with distilled water and to visualize proteins, the 
membran was stained with ponceau S (0.5 g/l ponceau S (Sigma), 1 ml/l glacial acetic 
acid) for 20-30 min, which was removed after the staining procedure by rinsing the 
membrane with distilled water. By copying the air dried membrane, the staining was 
recorded. Then the membrane was reactivated with methanol. To avoid unspecific 
binding the membrane was blocked with TBS-T (TBS: 8 g/l NaCl, 0.2 g/l KCl, 3 g/l 
Tris, pH 7.4; T: 0.1% Tween 20 (Sigma)) containing 5% skimmed milk powder (Fluka) 
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under gentle agitation for 1 hour at RT. To remove the blocking solution the 
membrane was washed 3 times with TBS-T (5 min each).  
 
Antibody incubation 
 
Incubation with primary antibody (Table 6), which was diluted in blocking solution, 
was performed at 4°C o/n. The next day the membrane was washed 3 times with 
TBS-T (10 min each) by shaking on a shaker and incubated with the secondary 
antibody (all used secondary antibodies were from Dako) for at least 1 hour at RT, 
followed by additional three washing steps with TBS-T and one washing step with 
TBS (8 g/l NaCl, 0.2 g/l KCl, 3 g/l Tris, pH 7.4) to remove antibody surplus. Finally 
the membrane was incubated with equal amounts of enhanced chemiluminescent 
(ECL) solution 1 and 2 (Immun-Star WesternC Kit, Biorad) for at least 3 min and the 
luminescence was detected on X-ray film.  
 
Table 6: Primary antibodies for Western Blot analysis 
Antibody Supplier Species Dilution 
Anti - ActβA Vale rabbit 1:5000 
Anti - ActβE SDI rabbit 1:1000 
Anti - pSMAD2/3 Cell Signaling rabbit 1:1000 
Anti - TotalSMAD Cell Signaling rabbit 1:1000 
Anti - Histidin  murine 1:1000 
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4.3. Cell biology 
 
4.3.1.  Cell lines and media 
 
Cell lines in Table 7, obtained from the cell culture unit of the institute of cancer 
research, were cultured at 37°C under a humidified condition of 95% air and 5% CO2, 
except SF9 insect cells, which were cultured at 27°C without CO2. The cell lines were 
routinely subcultured and kept at subconfluency using PBS (137 mM NaCl, 2.7 mM 
EDTA, 10 mM Na2HPO4, pH 7.4) for washing and Trypsine-EDTA for detaching of 
the cells. Additives in table 8 were added as appropriate. 
 
Table 7: Cell lines and media 
Cell line Origin Medium 
HEK293 
Human embryo renal cortical cells (Graham et al., 1977) DMEM; [Dulbecco's 
modified Eagle's medium, 
(Sigma)] 10% FCS (PAA) 
Hep3B 
Human hepatoma cell line (Knowles et al., 1980) RPMI [Roswell Park 
Memorial Institute 
medium, (Sigma)]; 10% 
FCS (PAA) 
HepG2 
Human hepatoma cell line (Knowles et al., 1980) MNP [MEME (Sigma)- 
Minimum Essential 
Medium Eagle- 
additionally 1 mM 
sodium pyruvate (Sigma); 
1% non-essential amino 
acids (PAA) ]; 10% FCS 
(PAA) 
K562 Human myelogenous leukemia cell line (Lozzio et al., 1979) RPMI; 10% FCS (PAA) 
Sf9 
Ovarian cell line from Spodoptera frugiperda (Vaughn et al., 
1977) 
Insect Express (PAA); 
10% FCS (PAA) 
 
 
 
Table 8: Additives to growth media 
Antibiotic Supplier Final concentration 
Puromycin PAA 0.4-0.6 μl/ml (1x) 
Penicillin/Streptomycin (P/S) PAA 10 μl/ml (1x) 
G418-Neomycin PAA 500 μg/ml 
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Tissue culture flasks - sizes T 25 (25 cm2), T 75 (75 cm2) and T 175 (175 cm2) - were 
bought from Greiner Bio-One and BD Falcon. 6-, 12- and 24-well plates were bought 
from IWAKI and 96 well-plates from PAA. 
 
4.3.2.  Freezing 
 
For long-term storage of positive stable cell clones, cells were grown in T 25 tissue 
flasks in respective full medium until almost fully confluent. Subsequently cells were 
detached (Trypsin/EDTA), resuspended in medium with 10% serum and containing 
DMSO (final concentration 50 μl/ml, Amresco) and transferred quickly to cryo tubes 
(Greiner) each with 1 ml. Cells were cooled down to -80°C over night and then 
transferred into the liquid nitrogen tank.  
 
4.3.3.  Thawing 
 
Ampoules taken out of the liquid nitrogen were thawn in a lukewarm water bath. 
Immediately, when the cell suspension was thawed, the content was transferred into 
a 15 ml tube (Falcon) containing 7-10 ml growth medium and centrifuged at 850 rpm 
for 4 min. The supernatant was removed and the cells resuspended in 6-7 ml fresh 
culture medium, which was stored at 37°C before usage. Cells were transferred to a T 
25 flask and incubated in a humidified incubator, paying attention to not agitate the 
flasks for at least 24 hours. The next day the medium was removed and replaced 
with fresh full growth medium.  
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4.3.4.  Cell counting 
 
Cell counting was performed on the one hand via Neubauer chambers (Paul 
Marienfeld GmbH), on the other hand for specific assays via a multichannel Casy cell 
counter (Schärfe Systems, Reutlingen, Germany). 
 
4.3.5.  Transfection procedure and generation of stable clones 
 
To introduce nucleic acids into cells and generate stable clones, mammalian adherent 
cells were transfected using either Lipofectamine 2000 (Invitrogen), Fugene 6 (Roche) 
or Turbofect (Fermentas) according to the manufacturers´ instructions. In brief, one 
day before transfection 5 x 105 cells were plated on each well of a 6-well-plate to gain 
a certain confluence at time of transfection. The next day a plasmid DNA – medium - 
transfection reagent mixture, prepared according to instructions, was distributed 
dropwise onto the cells. 48 hours after transfection the medium of transfected cells 
was changed to selection medium containing the respective antibiotic and gene 
expression was evaluated. Since the bicistronic vectors coded additionally for green 
fluorescent protein (GFP) every two or three days the cells were monitored by 
fluorescence microscopy. If necessary, the selective medium was changed and after 
forming of small GFP- expressing clones they were left to grow fully confluent for 
further sorting with fluorescence activated cell sorting (FACS) for GFP-positive cells. 
All used media contained penicillin and streptomycin (P/S) to prevent bacterial 
infections.  
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4.3.6.  FACS sorting 
 
For FACS sorting 5 l filtered 1x PBS, 2 l filtered 70% ethanol and 2 l filtered distilled 
water were prepared. Additionally 50 ml Falcon tubes containing 35 ml growth 
medium with 10% FCS were incubated over night at 4°C. Before sorting, the cells 
were detached (Trypsin/EDTA), pelleted and washed once with 1 x PBS. Afterwards 
the pellet was resuspended in 1 ml serum-free medium containing 
penicillin/streptomycin. The growth medium in the 50 ml Falcon tube was removed 
and instead 5 ml of medium containing penicillin/streptomycin were filled in each of 
the prepared tubes. Also untransfected cells were prepared for FACS analysis as 
negative controls. FACS tubes (BD Falcon) containing the cells and falcon tubes 
containing the growth medium were stored on ice and brought to the FACS analysis 
and sorting unit (Dr. Herbacek Irene). An appropriate number of GFP-positive cells 
was sorted and subsequently centrifuged at 800 rpm (Beckman CS-6KR Centrifuge) 
for 5´. The hardly observable pellet was resuspended in growth medium containing 
penicillin/streptomycin and G418 and transferred to a fresh culture dish, the size of 
which depended on the cell number. 
 
4.3.7.  RNA extraction  
 
All steps were performed with the usage of filter tips. Total RNA isolation from 
tissue culture cells was performed with Trizol (Invitrogen) reagent according to the 
manufacturer´s protocol. After the medium was discarded cells were washed with 1 
x PBS and Trizol (1 ml per T25 culture dish) was added onto the cells which were 
scraped into the Trizol suspension and incubated for 5 min at RT. The lysate was 
transferred into a 2 ml tube (Eppendorf) and incubated for 10 min with 0.2 ml 
chloroform/isoamylalcohol (50:1) per ml Trizol used. With a first centrifugation step 
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(12 000 g, 4°C, 15 min) cell debris were pelleted and the aqueous supernatant 
transferred into a new tube. 0.5 ml isopropanol per ml used Trizol were added to the 
transferred supernatant, inverted for nearly 20 seconds (sec) and incubated for 10 
min at RT. The precipitate was centrifuged (16 000 g, 4°C, 10 min), the supernatant 
aspirated and the pellet washed with 1 ml 75% EtOH by an additional centrifugation 
step (15 000 g, 4°C, 7 min). The supernatant was discarded and the pellet air dried.  
The RNA pellet was resuspended in 15-50 μl nuclease-free water and stored at -20°C 
or at -80°C for long-term storage.  
Nanodrop RNA measurement was used to determine RNA concentration by 
absorbance at 260 nm. To ensure integrity 1 μg RNA was analyzed on a 1.5% agarose 
gel. RNA secondary structures were resolved through treatment of diluted RNA (ad 
5 μl with nuclease-free H2O) with 5 μl urea loading buffer (2 x TBE, 7 M Urea, 13% 
ficoll or 15% glyecrol) and incubation at 70°C for 3 min. RNA was loaded with 2 μl 
Vistra-Green onto the gel and gel electrophoresis was performed as described above.  
The RNA was visualized by Typhoon Trio imager (GE Healthcare).  
 
 
4.3.8.  cDNA synthesis 
 
2 μg RNA were diluted with nuclease-free H2O to a total volume of 13 μl and 
incubated at 70°C for 10 min for denaturation. After that, samples were put on ice for 
5 min. A reverse transcription mix containing 4 μl 5 x buffer (M-MLV-Promega), 1 μl 
M-MLV reverse transcriptase (200 u/μl), 0.5 μl ribolock RNase inhibitor (40 u/μl MBI) 
and 0.5 μl random hexamers (1 μg/μl working stock) was added to the sample and 
incubated at 42°C for 1 hour for the transcription procedure. The reaction was 
stopped by additional incubation at 70°C for 10 min and 20 μl nuclease-free H2O 
were added to gain a total volume of 40 μl.  cDNA quality was tested by performing 
RT-PCR with primers for a housekeeping gene followed by agarose gel 
electrophoresis. cDNA aliquots were stored at –20°C. 
51 
 
4.3.9. Expression anlaysis: quantitative RT-PCR 
 
Quantitative real time polymerase chain reaction procedures were always carried out 
wearing gloves and using filter tips (Starlab).  
SYBR-Green-qPCR 
A mastermix containing nuclease-free H2O, SYBR-Green Master Mix and respective 
upstream and downstream primers (each 20 μM) (Table 9) were mixed on ice. In 
each well of a 96-well plate 1 μl cDNA was pipetted in duplicates for each sample, in 
selected wells nuclease-free water was pipetted instead of cDNA and served as 
negative control. The prepared master mix was added to the cDNAs and the plate 
subjected to PCR by using an ABI 7500 Fast PCR System 1.4 according to the 
manuals. Used primers are listed in the table 9 below. 
 
TaqMan-qPCR: 
A mastermix containing nuclease-free H2O, TaqMan qRT-PCR Mastermix and the 
respective TaqMan (Assay-ID´s in table 10) probe was prepared on ice. In each well of 
a 96-well plate 1 μl cDNA was layered in duplicates for each sample. In selected 
wells nuclease-free water was pipetted instead of cDNA and served as negative 
control. The prepared master mix was added to the cDNAs and the plate subjected to 
PCR by using an ABI 7500 Fast System 1.4 according to the manuals. The 
fluorescence was measured after each cycle and evaluated with ABI 7500 Fast 
System.  
As control for cDNA integrity and for normalization, B2M (Beta-2 microglobulin) or 
GAPDH TaqMan probes or respective primers for SYBR-Green qPCR were used. The 
qRT-PCR reactions were conducted with the cycling parameters shown in table 11. 
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Table 9: Primer used for SYBR-qPCR 
Gene Primer sequences Fragment size (bp) 
INHBE 
5´GAGACTACAGCCAGGGAGTG-3´/ 
5´CCCAGTTCCTGGAAGTCTAC-3´ 
548 
GAPDH 
5´CTGGCGTCTTCACCACCAT-3´/ 
5´GCCTGCTTCACCACCTTCT-3´ 
499 
 
Table 10: TaqMan probes used for TaqMan-qPCR 
Gene of interest Assay ID of TaqMan probe 
INHBE Hs00368884_g1 
B2M Hs00984230_m1 
 
Table 11: qRT-PCR parameters 
Step Temperature/Time Cycles 
Initial Denaturation 95°C/ 10 min 1 x 
Denaturation 95°C/ 15 sec 
40 x Annealing 60°C/ 30 sec 
Elongation 72°C/ 30 sec 
 
4.3.10.  Knockdown of βE with sh-lentiviruses 
 
Lentiviral shRNA vectors were used for long-term silencing and gene knockdown 
studies.  
Puromycin titration: 
First of all a puromycin kill curve was generated for the cell lines selected for 
knockdown. 16 000 cells in 120 μl full medium were plated in each well of a 96-well 
plate. The next day various concentrations (0.1, 0.2, 0.4, 0.6, 0.8 and 1 μl/ml) of 
puromycin were added to selected wells. The cell viability was examined 
microscopically every two or three days and five days after antibiotic treatment cell 
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viability was examined with the usage of MTT reagent (EZ4U, Biomedica) according 
to the manufacturer´s instructions and as described below. The minimum 
concentration of puromycin that caused 90-100% cell death was used further for 
selection of lentivirus-transduced clones.  
Lentiviral transduction 
1.6 x 104 cells in full medium were pipetted into the wells of a 96-well plate in 
duplicates one day before transduction in the case of adherent cells and at the day of 
transduction in the case of non-adherent cells. At the day of transduction, full 
medium was removed (by centrifugation and aspiration in case of non-adherent 
cells), replaced with 110 μl medium containing 8 μg/ml hexadimethrine bromide and 
incubated for 10 min at 37°C. Finally cells were transduced with a range of volumes 
(2-5 μl) of lentiviral particles to determine the optimal transduction efficiency; 
selected wells were not transduced and served as control. The plate was incubated 
for 24 hours at 37°C in an atmosphere of 5% CO2. The next day medium was 
removed and replaced with fresh medium containing puromycin.  This procedure 
was repeated every 3 or 4 days until only resistant colonies remained. Resistant 
clones were subjected to qRT-PCR to examine knockdown efficiency, expanded for 
further analysis and frozen for long-term storage.  
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4.4. Functional characterization of stable clones 
4.4.1. Cell vitality and proliferation 
4.4.1.1. MTT 
MTT cell viability assay was performed by using 3-(4,5 dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (EZ4U reagent, Biomedica). Briefly, 500-1 500 cells were 
seeded in each well of a 96-well plate in –at least- triplicates for each clone. Cells 
were grown for 24 hours and medium was changed to fresh medium (0.1%, 1%, 10% 
serum concentrations). The cells were incubated for four or five days at 37°C, 
medium only served as blank control. For detection of living cells incubation with 
EZ4U solution was carried out for 3-5 hours and the extinction was measured at 450 
nm and 620 nm as reference by using a SynergyHT microplate reader (BioTEK). The 
obtained data were saved and reported with Gen5 (BioTEK) software.  
 
4.4.1.2. Proliferation 
To elucidate the cumulative cell number after several times of passaging, cells were 
seeded in 6-well plates or T25 tissue culture flasks- dependent on their proliferation 
speed- at a certain density (70 000 – 150 000 cells /well of 6-well plates; 500 000 cells 
per T25). Every 2nd day cells were trypsinized and resuspended in full medium and 
an aliquot of 50 μl was subjected to analysis by the Casy cell counter. The primary 
seeded number of cells or a smaller number were reseeded for all samples and the 
cell counting and reseeding procedure was repeated every second day, trying to have 
at least four time points. Cumulative cell numbers were calculated from the cell 
counts plus diluton factors and growth curves were created with Graphpad Prism 5 
software.  
 
55 
 
4.4.2.  Clonogenic survival 
 
To analyze the proliferation of adherent cells by their capability to form colonies on 
tissue culture plastic, clonogenic survival assays were performed. 1 000-3 000 cells 
were seeded in each well of a 6-well plate in 2 ml growth medium. When a desired 
clone sizes were reached cells were fixed and stained with crystal-violet. For this, 
cells were washed with 1 x PBS and fixed with methanol/acetic acid (3:1) and further 
stained with 0.1% crystal violet in PBS. Cells were dried and the clonogenic growth 
behavior documented by photography (Nikon). Clones which were above a specific 
threshold were counted and after solubilization of the dye with 2% SDS absorption 
measured photometrically at 560 nm. Unstained wells subjected to 2% SDS as well 
served as blank controls.  
 
4.4.3.  Cell cycle analysis: Propidium iodide (PI) staining and 
flow cytometry 
 
For PI staining cells were detached, resuspended in 5 ml cold 1 x PBS and pelleted (1 
200 rpm, 4°C, 5 min.). The supernatant was removed and the pellet resuspended in 
cold 70% ethanol for fixation. Fixation was performed either through storage for at 
least 30 min at 4 °C or over night at -20°C. Prior to staining, cells were pelleted (1 200 
rpm, 4°C, 5 min.) and the ethanol-containing supernatant was aspirated. The cells 
were washed with at least 2 ml cold PBS to remove remaining ethanol with another 
centrifugation step at the same conditions as before. After removing the supernatant 
cells were stained with 0.5 ml PI staining solution (0.5 ml cold 1 x PBS, 2.5 μl RNAse 
A (10 mg/ml stock), 10 μl propidium iodide (2.5 mg/ml stock)) in round-bottom 
FACS tubes (BD Falcon) which were incubated 10 min at 4°C before measurement 
(Dr. Herbacek Irene). 
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4.4.4.  Migration 
4.4.4.1. Transwell assay 
 
The migratory phenotype of cells was analyzed by transwell assays. The transwell 
chambers fitted into wells of 24-well plates. 800 μl medium were added into one well 
of the tissue culture plate. The transwell chamber was placed into the well and 20 000 
cells in 200 μl medium were pipetted onto the porous membrane. Incubation time 
was dependent on the migratory behavior of cells and thus necessitated daily 
monitoring via microscopy. When a low and countable amount of cells had passed 
the membrane, the filter was removed and the cells were incubated 24-48 hours 
longer before staining with crystal violet.  Staining and migration results were 
documented on photographs.  
 
4.4.4.2. Wound healing assay 
 
The migratory phenotype of cells which correlates with metastatic and invasive 
phenotype was also evaluated by a so called wound healing or scratch assay. The 
assay was performed in 6-well plates. Confluent cell monolayers were scraped with a 
blue pipette tip and 3 or 4 scratches of about 1 cm length were created. Subsequently 
cells were washed to remove detached cells and wound closure was monitored by 
microscopy at various time points (0 h, 24 h, 48 h, 72 h). Wound closure was recorded 
on photographs and analyzed with ImageJ software and Graphpad Prism software.  
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4.4.5. Soft Agar 
 
Soft agar assay to analyze adherence-independent colony formation behavior was 
performed in 6- well plates. Two water baths were used to keep solutions at the 
required temperatures. Realization of the assay lasted two days and on the first day 
the bottom agar was prepared as follows. For a total volume of 50 ml Soft Agar 
medium 10 ml 10 x RPMI medium (Sigma), 2 ml NaHCO3, 1 ml glutamine, 17 ml 
autoclaved distilled H2O and 50 μl folic acid were mixed, brought to a pH value of 8 
and then filter-sterilized. Subsequently 20 ml FCS and 1 ml P/S were added and the 
medium was stored in a 37°C water bath. 1.2% agar solution was prepared and 
solubilised by boiling and stored at 40°C. The agar solution and soft agar medium 
were mixed 1:1 and 1.5 ml of agar-medium dilution pipetted into each well of the 6-
well plate. Attention was paid to avoid air bubbles in the bottom agar, to avoid too 
fast cooling of the dilutions during pipetting and to properly distribute the bottom 
agar through gentle agitation of the plate. Plates were incubated over night at 37°C.  
The next day the top agar was prepared. 5 000 -10 000 cells were pelleted (800 rpm, 5 
min, RT) and resuspended in 750 μl Soft Agar medium which had 37°C. The agar 
solution (1.2%) was diluted 1:1 with autoclaved distilled H2O and 750 μl of it were 
added to the cell suspension which had then a total volume of 1.5 ml.  Cells were 
distributed onto the bottom agar by gentle agitation, stored for 3 min in the fridge 
and then put into the incubator. Clone sizes were monitored (over 4-8 weeks 
dependent on the cell line), clones were counted under the microscope and 
documented by photography.  
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4.4.6.  Treatment with the demethylating agent 5´-azacytidin 
 
Due to the fact that vβE overexpressing cells lost vβe expression by and by 
demethylation with 5´-azacytidin was performed to evaluate epigenetic regulation of 
vβE. 15 x 104 stable transfectants, control cells (mock transfected or expressing 
scrambled shRNA), and not-transfected cells (NTC) were seeded per well of a 12-
well plate in 1 ml full medium and incubated at 37°C for 24 hours.  The next day 
medium was replaced with serum-free medium containing 0.5 μM 5´-azacytidin 
(dissolved in DMSO).  Treatment was performed in duplicates and renewed every 48 
hours and since the bicistronic plasmid expressed GFP the effect of demethylation 
was monitored with fluorescence microscopy.   
 
4.4.7. Statistical analysis 
 
Graphpad Prism 5.0 software (Graphpad Software Inc.) was used for statistical 
calculations and evaluation of significance. P-values < 0.05 were considered to be 
significant and were marked with an asterisk. 
 
4.5. Transcriptome analysis: Microarray   
 
Expression profiling was performed using microarrays (Agilent Technologies) to find 
potentially regulated target genes of βE. 44K whole human genome arrays which 
contain 44 thousand probes and are based on DNA-RNA hybridization were used. 
We performed two color experiments, where one of the samples was labeled with 
Cyanine 3-CTP (Cy3) and the other one with Cyanine 5-CTP (Cy5) fluorescent dye.  
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Before RNA isolation, cells were seeded in T25 tissue culture flasks at equal density 
and growth medium was changed at regular intervals to keep cells in optimal 
conditions. RNA isolation was performed using Trizol reagent and then RNA 
precipitation was carried out as described above. To analyze RNA integrity 150-500 
ng RNA were analyzed with Agilent Bioanalyzer 2100 to determine the RNA 
integrity number (RIN).  
Sample combinations were performed according to table 12: 
Table 12: Pipetting scheme of one 4 x44 k expression array 
 Array 1 Array 2 Array 3 Array 4 
Cy3-labeling Mock or Scrambled Mock or Scrambled NTC βE overexpression 
or knockdown 
Cy5-labeling βE overexpression  
or knockdown 
NTC βE overexpression 
or knockdown 
Mock or Scrambled 
 
All steps were carried out on ice, using gloves and filter tips. Working with labeling 
dyes was performed under “dark” conditions. At first Spikes, which were used to 
integrate corresponding labeling dye during cDNA synthesis, were diluted 
according to table 13:  
Table 13: Spike dilution preparation 
Dilutions Components 
Dilution 1 2 μl Spike A or B + 38 μl Dilution buffer (1:20) 
Dilution 2 2 μl of dilution 1 + 78 μl Dilution buffer (1:40) 
Dilution 3 10 μl of dilution 2 + 30 μl Dilution buffer (1:4) 
 
Spike A correlates with Cy3 and Spike B with Cy5. For 3 RNA samples (Mock, NTC 
and respective clone) 6 μl Spike A or Spike B of dilution 3 were mixed with 3.6 μl of 
T7 promoter primer. Additionally 1500 ng of each RNA sample was diluted with 
nuclease-free H2O to a total volume of 8.3 μl and mixed with respectively 3.2 μl of 
Spike A or B. The samples were incubated for 10 min at 65°C and then for 5 min on 
ice. For cDNA synthesis a cDNA mastermix was prepared according to the table 
below: 
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Table 14: cDNA mastermix 
Component μl per reaction Comments 
5 x First Strand buffer 4 Prior to usage the buffer was 
incubated at 80°C for 3-4 
min.  
0.1 M DTT 2  
10 mM dNTP mix 1  
MMLV-RT 1  
RNase Out 0.5  
 
8.5 μl of the cDNA mastermix were added to each sample and gently resuspended. 
The samples were incubated at 40°C for 2 hours and then the reaction was stopped 
by additional incubation at 65°C for 15 min. cDNAs were stored at -20°C until 
needed for the transcription reaction. After cDNA synthesis the total volume 
amounted to 20 μl, whereof 10 μl were stored as backup at -20°C and the remaining 
10 μl were used further. A transcription mix was prepared as shown in table 15. 
Table 15: Transcription mastermix 
Component μl per reaction Comments 
nuclease-free water 7.65  
4x transcription buffer 10  
0.1 M DTT 3  
NTP mix 4  
50% Polyethylenglycol (PEG) 3.2 Prior usage PEG was incubated 
at 40°C for 1 min. 
RNase inhibitor 0.25  
Inorganic pyrophosphatase 0.3  
T7 RNA Polymerase 0.4  
Cy3-CTP or Cy5-CTP 1.2  
 
30 μl of transcription mix were added to each 10μl “spiked” cDNA and the 
transcription reaction was carried out at 40°C for 2 hours. Subsequently labeled RNA 
was purified by RNeasy kit (Quiagen) according to the manufacturer´s instructions 
and the purification yielded 30 μl of RNA solution. The labeled cRNAs were 
quantified with a specific nanodrop measurement for labeled RNAs and the dye 
incorporation was calculated as follows: 
Formula: Concentration of Cy3 or Cy5 (pmol/μl) 
                 Concentration of RNA (ng/μl) x 1000        = pMol Cy3 or Cy5/ μg RNA  
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(cRNAs should have an incorporation value above 8 pMol dye/μg RNA for the 
hybridization procedure).  
Before hybridization a fragmentation reaction was carried out to fragment cRNA. For 
better handling, cRNAs were diluted to 100 ng/μl. The following fragmentation mix 
was pipette (Table 16).  
Table 16: Fragmentation mix 
Reactant μl  
Cy3 cRNA 8.25 (825 ng) 
Cy5 cRNA 8.25 (825 ng) 
10 x blocking reagent 11 
Nuclease-free H2O 25.3 
25 x fragmentation buffer 2.2 
Total volume 55 μl 
 
The fragmentation reaction was incubated at 60°C for 30 min and the reaction was 
stopped by adding 55 μl of 2 x Gex Hyb buffer HI-RPM (Gene Expression 
Hybridization Kit, Agilent). The samples were put on ice and loaded on the array as 
fast as possible. 100 μl of each reaction were dispensed onto one of the four marked-
off areas of the gasket well, which had been inserted into a chamber before. The array 
slide was placed onto the gasket well, so that the active side lay on the reaction 
suspension, and the assembly was closed. Bubbles were removed by tapping gently 
or mobility of bubbles was assessed by rotating the chamber. The array was 
hybridized in a hybridization oven at 65°C for 17 hours at 20 rpm. The next day the 
array slide was washed in Agilent buffers as follows: The slide was separated from 
the gasket well in Washing Buffer 1 and incubated in another dish containing fresh 
Washing Buffer 1 and a rack for 2 min while a stirrer gently mixed the solution. Then 
the slide, without any liquid drops on it, was transferred into Washing Buffer 2 and 
incubated for exactly 1 min by gently stirring.  Subsequently the slide was 
transferred into acetonitril for exactly 1 min, dried shortly at RT (1 min) und put into 
a slide holder with the barcode facing up. After hybridization slides were scanned 
with two different lasers and detectors, one for each dye. Fluorescence signals were 
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captured in a TIFF picture which was extracted into a text file with Feature extraction 
software. This text file was loaded into Genespring GX 11 software, where a range of 
statistical analyses was carried out. 
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5.  Results 
 
5.1. Construction of expression vectors 
 
5.1.1. βE into IRES-EGFP 
The vector pIRES-HsAβE (Figure 6) containing the human βE coding region was used 
for cloning of the βE subunit into the pIRES-EGFP vector (Figure 7). As both the 
template and the target vector contained a CMV promoter upstream of the gene of 
interest a restriction site (NdeI) which cuts inside the promoter region could be used 
for the 5´ end. The digestion procedure for both vectors was carried out with the 
usage of NdeI and EcoRI restriction sites with further elution out of a 1% preparative 
agarose gel (Promega Kit) (Figure 8). The expected restriction fragments – 1771 bp 
and 4773 bp in the case of pIRES-HsAβE, and 395 bp and 4913 bp for pIRES-EGFP – 
were visible on agarose gel and nanodrop measurement resulted in 201.8 ng/μl IRES-
EGFP vector DNA and 13.9 ng/μl hsβE insert DNA. After ligation and 
transformation into JM109 competent E.coli cells, a plasmid quick- mini preparation 
of overnight cultures and subsequent control restrictions with SnaBI restriction 
enzyme of five clones was carried out (data not shown). Two possible positive clones 
producing the expected fragment sizes – 1206 bp, 5748 bp - on an agarose gel were 
used to prepare again over night cultures and to conduct plasmid mini preparations 
with the Promega Kit. Subsequent control restrictions with SnaBI, HindIII and 
Eco47III resulted in the observation of nearly the anticipated fragments: SnaBI 1212 
bp, HindIII 1628 bp, Eco47III: 967 bp (Figure 9). The sequencing report for the βE 
construct by Mycrosynth confirmed that the 1052 bp product was the open reading 
frame of the human βE subunit (Figure 10) and manual inspection of undefined bases 
in the chromatogram confirmed the absence of mutations. The newly constructed 
vector pHsβE-IRES2-EGFP is shown in Figure 11. 
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Figure 7: pIRES-EGFP target vector and 
mock control. 
Figure 8: Preparative agarose 
gel: Lane 1: pIRES-HsAβE 
vector restricted with NdeI and 
EcoRI (50 µl DNA + 10 µl 
VistraGreen), Lane 2: pIRES-
HsAβE unrestricted, Lane 3: 
1kB Marker, Lane 4: pIRES-
EGFP restriction by NdeI and 
EcoRI, (1% agarose gel in 0.5x 
TBE). 
 
Figure 9: Plasmid preparation and 
restriction of two possible clones with 
respectively SnaBI, HindIII or 
EcoR47III: Lane 1: 1kB Marker, Lane 2: 
unrestricted plasmid DNA of clone 1, 
Lane 3: clone 1-SnaBI restriction, Lane 
4: clone 1-HindIII, Lane 5: clone 1- 
Eco47III, Lane 6: unrestricted plasmid 
DNA of clone 2, Lane 7: clone 2-SnaBI 
restriction, Lane 8: clone 2-HindIII 
restriction, Lane 9: clone 2-Eco47III 
restriction (1% agarose gel in 0.5x TBE). 
 
Figure 6: Template vector pIRES-HsAβE 
containing the human βE-subunit. 
1kB 
1kB 
1771bp 
4773bp 
395bp 
4913bp 
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Figure 11: Cloning product vector pHsβE-IRES-EGFP. 
Figure 10: Nucleotide sequencing report: Alignment analysis based on sequencing report results and pIRES-HsAβE 
vector as reference, and subsequent chromatographic analysis of undefined (“n”, see red arrows) bases for point 
mutation. 
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5.1.2. vβE into IRES-EGFP 
 
For construction of a bicistronic expression vector we amplified the coding region of 
the human vβE (also termed altβE for alternative transcript of the beta E gene) by 
PCR. The vector pCMV-Sport6-altβE (Figure 12) was used to design primers to 
amplify the coding region of vβE including the ATG and adding an EcoRI restriction 
site. The following primers were used: a 5´end specific forward primer adding an 
EcoRI restriction site upstream of the ATG (5´ 
CCCGAATTCCGCCATGCTAGAAATAAAGAGACCAGA- 3´) and a 3´ end specific 
reverse primer including the stop codon and adding a BamHI site (5´ 
TTTGGATCCTAGCTGCAGCCACAGGCCTC-3´). Before performing a Pfu- PCR, an 
amplification procedure with Taq polymerase was analysed by gel electrophoresis 
and showed bands around 1kb (data not shown). Repetition of the PCR procedure 
with Pfu Polymerase provided fragments with the same size on agarose gel (Figure 
13). The PCR product was again subcloned into an IRES-EGFP vector (Figure 6). For 
ligation restriction digests with BamHI and EcoRI restriction enzymes were 
performed for the target vector pIRES-EGFP and the PCR samples. Subsequently 
they were purified out of a preparative gel (Figure 14). The nanodrop measurement 
resulted in 70 ng/μl pIRES-EGFP vector DNA and 6 ng/μl vβE insert DNA. The 
ligation as indicated above led to fusion of DNA molecules which were transformed 
into E.coli JM109 cells and then plated on selective media containing kanamycin for 
selection of plasmid-containing cells. For quick selection of potential positive clones 
containing the insert of interest, a “quick preparation” of plasmid DNA was 
performed and plasmid DNA was restricted once with HindIII and once with Eco47III 
and analyzed on a 1% agarose gel (Figure 15). Eco47III digested the vector two times 
and the expected fragments were of 170 bp and 6085 bp lengths. The fusion product 
contained also two HindIII restriction sites yielding fragments of 1216 bp and 5039 bp 
lengths. Two clones, 1 and 8 were identified as producing bands of the expected 
lengths (although the 170 bp fragment was not detectable in the gel) and 
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subsequently overnight cultures for minipreparation with the Promega Kit were 
prepared. Plasmid DNA of clone 1 and 8 was isolated and restricted again with the 
enzymes BamHI and EcoRI and analyzed by gel electrophoresis (data not shown). The 
expected fragment of 978 bp length after this restriction was received by both clones 
and so a sample (0.8 μg in 10 μl nuclease-free H2O) was sent to Mycrosynth for 
nucleotide sequencing and screening for mutations. For sequencing, CMV forward 
and reverse primer were used. Nucleotide sequencing results were checked with 
Alignment analysis in Clonemanager (Sci-Ed Software) and subsequent manual 
inspection of ambiguous nucleotides in the chromatogram, which confirmed the 
absence of mutations (Figure 16). The newly constructed vector pHsvβe-IRES2-EGFP 
is shown in Figure 17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: pCMV-Sport6-altβE 
vector containing the alternative 
βE subunit. 
 Figure 13:  PCR amplification of vβE 
subunit with Pfu-polymerase: Lane 1: 
1kB Marker, Lane 2-5: PCR product, 
(1% agarose gel in 0.5x TBE). 
Figure 14: Vector pIRES-EGFP 
restriction digest with BamHI and 
EcoRI: Lane 1: pIRES-EGFP restriction, 
Lane 2: pIRES-EGFP unrestricted, Lane 
3: 1kB Marker, (1% agarose gel in 0.5 x 
TBE) 
 
1kB 1kB 
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Figure 17: newly constructed fusion 
product: vector pHsvβE-IRES-EGFP. 
Figure 15: Plasmid “quick-preparation” of eight clones and restriction with respectively HindIII or Eco47III to screen 
for potential positive clones containing pvβE-IRES-EGFP vector: Lane 1: 1kB Marker, Lane 2-9: Eco47III restricted 
plasmids of different clones, Lane 10: empty, Lane 11-16: HindIII restriction approaches with same plasmids gained by 
same clones, Lane 17: 1kB Marker, Lane 18-20: HindIII restriction, (1% agarose gel in 0.5x TBE).  
Figure 16: Nucleotide sequencing report: Alignment analysis based on sequencing report results and pCMV-
SPORT6-altβE vector as reference, and subsequent chromatographic analysis of undefined (“n”, see red arrows) 
bases for point mutation.  
1kB 1kB 
1216bp 
1216bp 
250bp 
69 
 
5.2.  Tet System reconstruction  
 
The Tet-Off Advanced Inducible Gene Expression System (Clontech) allows 
inducible expression of the gene of interest, where transcription can be reversibly 
turned on or off in presence/absence of tetracycline.  
5.2.1. inducible GFP 
In a first cloning approach, which was performed to simplify the system, the vectors 
pTet-Off Advanced (A99, Figure 18 a) and pTRE-Tight (A100, Figure 18 b) were 
digested and ligated to gain one plasmid containing the transactivator and the 
inducible promoter sequences (p pTet-Off-TRE-Tight).  
For that purpose 10 μg of the vector pTet-Off Advanced were restricted with 2.5 μl 
HindIII (10 u/μl) in buffer R (Fermentas) for 1.5 hours at 37°C. At the same time a 
preparative digest was carried out for 2 μg vector pTRE-Tight with XhoI enzyme. 
Both digestive approaches were inactivated by incubation at 80°C for 20 min and 
subjected to Klenow Polymerase reaction to create blunt ends.  Vector pTet-Off was 
dephosphorylated additionally. Both products were loaded on an agarose gel and 
desired fragments were excised (data not shown). DNA purification yielded 14.1 ng/μl 
vector DNA pTet-Off and 18.8 ng/μl insert DNA containing the inducible promoter 
and the multiple cloning site from pTRE-Tight. Subsequently vector and insert DNA 
were ligated o/n at RT and then transformed into JM109 E.coli competent cells. The 
transformants were plated on ampicillin-containing agar plates. The next day 
colonies were picked from plates and o/n cultures were generated for further 
plasmid quick preparation. Prepared DNA was restricted with HpaI for control. One 
clone yielded fragment sizes of 414 bp, 2875 bp, and 4450 bp indicating the presence  
of the expected insert with the inducible promoter in antisense orientation with 
respect to the ORF of the transactivator (Figure 19). This clone was subjected to 
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plasmid Miniprep purification (Promega) which yielded 113.4 ng/μl DNA. Vector 
pTet-Off-TRE-tight-antisense is shown in Figure 20.  
A second cloning procedure was performed to clone GFP into the newly generated 
pTet-Off-TRE-Tight vector. 7 μg of vector pEGFP-N3 (A16) and of vector pTet-Off-
TRE-Tight were digested with enzymes NotI and KpnI in BamHI buffer. Additionally 
pTet-Off-TRE-Tight vector backbone was dephosphorylated. Both products were 
loaded on an agarose gel and desired fragments were excised (data not shown). The 
expected fragment sizes were 7695 bp and 44 bp for pTet-Off-TRE-Tight and 3981 bp 
and 748 bp for pEGFP-N3.  
DNA purification yielded 28.4 ng/μl vector DNA (pTet-Off-TRE-Tight) and 8 ng/ul 
insert DNA (A16). A rapid ligation kit was used to ligate vector and insert DNA, the 
ligation mixture was transformed into JM109 E.coli cells and transformants plated on 
ampicillin-containing agar plates. A quick minipreparation was performed with 
several clones and DNA digested with BamHI in unique BamHI buffer (data not 
shown). For one potential positive clone two control restriction procedures were 
performed, the first with EcoRI enzyme in unique EcoRI buffer and the second one as 
a double digest with NotI and KpnI in BamHI unique buffer. The expected fragments 
of the first approach were 2216 bp and 6235 bp, of the second approach 756 bp and 
7695 bp (Figure 21).   
 
 
 
 
 
 Figure 18: (a) Vector pTet-Off Advanced expresses constitutively the tetracycline-controlled transcriptional 
transactivator. (b) Vector pTRE-Tight contains the inducible promoter that controls the transcription of the 
gene of interest. 
a b 
 Overnight cultures were prepared from our positive clone for further preparation 
and glycerol stock generation. Newly generated vector pTet
shown in Figure 22. 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
Figure 19: Control restriction of newly 
generated pTet-Off-TRE-Tight with 
HpaI: Lane 1: 1kB Marker, Lane 2: 
empty, Lane 3: HpaI restricted clone. 
Expected fragment sizes of 414 bp, 2875 
bp, and 4450 bp were obtained and 
indicate an antisense orientation of 
insertion of insert DNA.  
Figure 21: Control restriction of newly 
generated pTet-Off-TRE-Tight
Lane 1: 1kB Marker, Lane 2: NotI and 
KpnI double digestion of clone with 
expected fragment sizes of 756 bp and 
7695 bp, Lane 3: EcoRI restriction of 
clone with expected fragment sizes of 
2216 bp and 6235 bp.  
1        2         3 
1        2         3 
1kB 
1kB 
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To investigate the activity of the newly generated vector, AKH3P cells were 
transfected with the vector pTet-Off-TRE-Tight-EGFP and selected with the antibiotic 
G418 for generation of stable clones. Expression of GFP was monitored under the 
microscope. Cells were expanded and after they had reached a certain density 
distributed to two culture flasks. In one of the culture dishes stable clones were 
treated with doxocyclin, which binds to the TRE sequence and blocks the 
transcription of the gene of interest, which was GFP in our case. 48-72 h after 
treatment with doxocyclin we did not observe inhibition of GFP-expression, which 
was due to the half-life of GFP, but gradually the GFP expression decreased and after 
4 days was markedly reduced. This was an indication that our newly generated 
plasmid pTet-Off-TRE-Tight contained all essential parts to serve as an inducible 
gene expression system.  
 
5.2.2. inducible alternative beta E 
 
Vector pTet-Off-TRE-Tight was used as target vector for cloning of the coding region 
of human vβE and GFP as insert and generation of an inducible gene expression 
system for the alternative βE transcript. In previous transfection procedures our 
pHsvβE-IRES-EGFP plasmids lost expression by and by after transfection in the 
respective mammalian cells. Thus we decided to use an inducible expression system. 
The cloning strategy was performed as follows: 5 μg vector pHsvβE-IRES-EGFP 
containing vβE were digested with 5 μl XhoI (Fermentas fast enzyme) and 5 μl HpaI 
(Fermentas fast enzyme) in 10 x fast digest buffer for 10 min on 37°C, expecting 
fragments of 2429 bp and 7735 bp. 5μg vector pTet-Off-TRE-Tight were digested in a 
first approach with EcoRV in buffer O for 4 hours, then the enzyme was inactivated 
by incubation at 80°C for 20 min and then 1.5 μl SalI restriction enzyme were added 
to the approach and digested further for another 1.5 hours. The expected fragments 
of the EcoRV-SalI double restriction were 7753 bp and 4 bp. Subsequently DNAs were 
 loaded onto an agarose gel, excised, purified and used for rapid ligation (vector pTet
Off-TRE-Tight yielded 35.77
nanodrop measurement). Ligations were transformed in
plated onto ampicillin containing LB plates. Quick minipreps were performed with 
clones which were subsequently digested with 
not shown). Three potentially positive clones were selected and digested 
expecting fragments of 3838 bp, 6235 bp and 87 bp lengths (
one was subjected to a minipreparation with 
The newly generated vector pTet
vector pTet-Off-TRE-Tight
storage for further investigation of the alternative 
no additional experiments were conducted during this diploma thesis. 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 23: Control restriction wi
EcoRI enzyme: Lane 1: 1kB, Lane 2
three different clones digested with 
EcoRI.  
      1            2           3           
1kB 
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5.3. Baculovirus Expression System: Construction of 
recombinant activins in insect cells 
 
With the BAC to BAC baculovirus system (Figure 25) we created recombinant 
baculoviruses for high level expression of His –tagged versions of activin βA and βE 
(Figure 26) in insect cells (SF9). Integration of DNA fragments into bacmids was 
accomplished in E.coli hosts via recombination into a lacZ gene on the bacmid and 
recombinant bacmids were identified by blue/white screening (Trowitzsch et al., 
2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 25: Schematic overview of the Bac to Bac expression 
system (Bac-to-Bac Expression Kit Handbook, Invitrogen life 
technologies).  
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5.3.1. Construction of Histidin-tagged activins  
 
First, purchased primers (Table 1) were tested by Taq- PCR (expected fragment sizes 
of the mature peptides = around 400 bp; propeptides around 800 to 900 bp; 
INHBA_His= 1400 bp; INHBE_His = 1100 bp, data not shown) and after verification 
the PCR products generated with Pfu-PCR. As PCR templates for activin beta A and 
activin beta E expression vectors containing the respective coding region for the 
individual proteins were used (Figure 27 a+b). For activin subunits with the Histidin-
tag (His-tag) in the middle (at the N-terminus of the mature peptides after proteolytic 
processing in the ER: His_INHBA, His_INHBE) two PCR rounds were performed to 
get the cassette. At first a PCR product of the propeptide with the His-tag at the C-
terminal-end and one of the mature protein with the His-tag at the N-terminal-end 
was generated. PCR products were loaded on an agarose gel, respective bands were 
excised and eluted with the promega purification kit. Then the His-tagged mature 
peptide and propeptide were mixed in one Eppendorf tube and this mixture served 
as the new template. Another Pfu-PCR with primers binding at the n- and c- 
terminus of the activin cDNAs was performed where finally activin cDNAs with the 
His-tag in the middle were gained. For the His-tag at the C-terminal-end 
(INHBA_His, INHBE_His) only one Pfu-polymerase PCR was performed. After 
elution of the DNA from the gel slices the desired fragments were obtained with 
their concentrations: Activin A constructs: His_INHBA [23 ng/μl], INHBA_His [11 
ng/μl]; Activin E constructs: His_INHBE [22 ng/μl]; INHBE_His [16 ng/μl]. The “His” 
at the beginning stands for the histidin tag in the middle of the construct, “His” 
designation at the end indicates a C-terminal histidin tag.  
 
 
 
 
Figure 26: For production of recombinat 
activin E or A two different approaches 
were conducted. In the first approach the 
recombinant protein was HIS-tagged 
between the pro- and mature peptide, and 
in the second approach at the C-terminal 
end of the mature peptide.  
First approach: Constructs designated 
His_INHBA or His_INHBE 
First approach: Constructs designated 
INHBA_His or INHBE_His 
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5.3.2. Restriction digest and transformation of JM109 E.coli  
 
The generated PCR products were cloned into the baculovirus transfer vector 
pFastbac-1. In fact the restriction sites EcoRI and StuI were used for further ligation 
with the activin A cassettes and EcoRI and HindIII with the likewise restricted activin 
E cassette. Restriction and ligation procedures were performed as mentioned above. 
The generated expression vectors were transformed into competent JM109 E.coli cells, 
which successively were plated on ampicilin containing LB - plates o/n at 37°C. For a 
Quick n´dirty plasmid minipreparation o/n cultures were generated and afterwards 
plasmids were restricted with HindIII for the activin βA-containing vectors and SnaBI 
for activin βE. Positive clones (marked as red arrows in the figures) of activin A 
cassettes = 1300 bp and activin E cassettes = 1100 bp (Figure 28-30) were identified 
and clean preparation of the plasmids followed. The DNA amounts of our activin 
vectors (His_INHBA = 4 ng/μl, INHBA_His = 9 ng/μl; His_INHBE = 9 ng/μl; 
INHBE_His = 8 ng/μl ) were measured with nanodrop and then sent for sequencing 
Figure 27: (a) Vector pHsaβE was used as PCR template for construction of His-tagged activin βE. (b): 
Vector pHsINHBA-IRES-puro was used as PCR template for construction of His-tagged activin βA. 
a b 
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to Microsynth. No mutations were detected in the activin cassettes; His_INHBE had 
only 5 instead of the intended 6 histidines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Control restrictions of plasmid minipreparations: Lane 
1+14: 1kB Marker, Lane 2-7: His_INHBE restricted with SnaBI, 
Lane 8-15: INHBE_His restricted with SnaBI, Lane 16-23: 
INHBA_His restricted with HindIII. Red arrows indicate 
fragments of expected length after restriction which were 1300 bp 
in the case of activin A cassettes and 1100 bp in the case of activin 
E constructs.  
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5.3.3. Transformation of the DH10Bac E.coli strain with activin 
plasmids  
 
Correct plasmids were subsequently transformed into the DH10 E.coli strain, the 
activin cassettes were inserted into the bacmid between two transposon sites. After 
incubation for 48h white colonies were picked and transferred with a pipette tip to a 
“grid” LB-plate (kanamycin [50 μg/ml], tetracycline [10 μg/ml], gentamycin [7 
μg/ml], Iptg [40μg/ml] and X-Gal [100 μg/ml]. The rest of the colony was diluted in a 
tube containing 15 μl PBS for colony PCR and colonies possessing the correct insert 
were subjected to an alkaline lysis minipreparation. The amount of bacmid DNA was 
analyzed by nanodrop measurement. 
 
 
 
 
Figure 29: Control restrictions of plasmid 
minipreparations: Lane 6: 1kB Marker, Lane 1-5 + 
7-10: His_INHBA construct restricted with 
HindIII. Red arrows indicate fragments of expected 
length after restriction which was 1300 bp. 
Figure 30: Control restrictions of 
plasmid minipreparations: Lane 1: 1kB 
Marker, Lane 2-7: INHBE_His 
construct restricted with SnaBI. Red 
arrows indicate fragments of expected 
length after restriction which was 1100 
bp. 
    1       2       3       4       5       6      7 
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5.3.4. Transfection of SF9 cells with bacmids  
 
SF9 insect cells were transfected with bacmids (Fugene6) coding for recombinant 
activin A or activin E. The backbones of the bacmids also expressed yellow 
fluorescence protein (YFP) and gradually the cells started having fluorescence under 
the microscope indicative of viral spread (Figure 31). Cells expressing the 
recombinant activin A construct outspeeded cells transfected with His-tagged activin 
E in expressing fluorescent protein. The latter took longer at many parallel 
transfection approaches, whereas most of the recombinant activin A transfected cells 
fluoresced soon.  
 
  
 
 
 
 
 
 
 
5.3.5. Investigation of expression and bioactivity of recombinant 
activins  
To analyze if the expression of recombinant proteins was detectable, protein was 
precipitated from SF9 cell supernatants and isolated from whole cell extracts. After 
determining the protein concentration with Bradford reagent assay, proteins were 
separated with SDS gel (12%) and detected with Western blotting. Anti-Activin A 
antibodies could detect activin A in samples precipitated from the SF9 cell 
supernatant, in the cell layer and directly in the supernatant of SF9 cells (without 
Figure 31: Microscopy of SF9 insect cells expressing recombinant activin and YFP.  
 precipitation) when SF9 cells were infected with activin A expressing baculovirus. 
The highest amount was found 
not shown). Due to the fact that there are no efficient antibodies against activin E 
Anti-Histidin antibodies were used to detect the His
(Figure 32).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The anti-Histidin and anti
baculovirus transfected cells, and not in the layer or 
cells. A bioactivity of the protein
pSMAD2 increase after treatment 
supernatant of recombinant activin A
Figure 32: Western Blot analysis of recombinant activ
incubated in serum-free medium (SFM) and after baculovirusoutbreak, which was visible 
under the microscope due to YFP expression, supernatant was precipitated with EtOH and 
protein-samples subjected to Western Blotting
(a) or histidin antibody (b). Supernatant of SF9 cells expressing recombinant protein into SFM 
medium was transferred to HepG2 cells and incubated for 30 min. Proteins were isolated from 
the cell layer and recombinant activin bioactivity was analyzed using anti
(c).   
 1     2      3     4      5  
    1       2      3 
   1      2      3     4 
a 
b 
c 
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after ethanol precipitation of cell supernatant
-tag of all recombinant proteins
-βA antibodies detected protein only in samples from 
supernatant
, however, was not detectable; there was no 
of activin A-responsive HepG2 cells 
-expressing SF9 cells. SMAD2 phosphorylatio
in A or E. Transfected SF9 cells were 
. Detection of protein with activin A antibody 
-pSMAD2 antibody 
pSMAD2 pSMAD 2: 1: His_Activin A, 
Activin A_His, 
supernatant, 4: rec. activin 
Systems), 5:  insect medium only
 
Activin βA 
Activin βA: 1: His_Activin A, 
Activin A_His, 
supernatant. Gel was run under non
reducing conditions. 
Histidin 
Histidin: 1: His_Activin A, 
A_His, 3: His_Activin E, 4: Activin 
E_His. Gel was run under
conditions. 
 (data 
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was only increased when cells were treated with a commercially available 
recombinant  activin A (R&D Systems, dissolved in 1x PBS containing 0.1% BSA). 
Both activin A constructs were detectable with respective antibodies when the gel 
was run under reducing conditions, and only His_INHBA was traceable under non-
reducing conditions (data not shown). Although we detected at least one dimerized 
His-tagged recombinant activin A, none of the constructs could achieve bioactivity. 
In the case of recombinant Activin E the histidine-tags were undetectable. As future 
outlook this approach has to be optimized. Mammalian cell lines have to be 
considered for production of recombinant activin proteins.  
 
5.4. Generation of stable clones and confirmation of 
overexpression or silencing 
5.4.1. Stable clones overexpressing βE and vβE 
 
The newly constructed plasmids pHsβE-IRES2-EGFP (Figure 11), pHsvβE-IRES2-
EGFP (Figure 17) and the already existing pIRES-EGFP (Figure 7) as mock control 
were transfected into Hep3B and HepG2 cells using Lipofectamine 2000. For 
generation of stable clones the cells were selected with the antibiotic G418 and 
confluent cultures were subjected to FACS sorting for GFP expressing cells. Due to 
the fact that the transfection efficiency of pHsvβE-IRES2-EGFP was very low  (Figure 
33) or GFP expression was lost after a short time we further analyzed and 
investigated only the role of βE overexpressing cell lines.  
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Except for vβE transfected cells many cells of the other two transfectants showed 
fluorescence and it was uncomplicated to sort those which demonstrated the highest 
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Figure 33: Transfection efficiency of 
pIRES-EGFP and pHsvβe-IRES2-EGFP 
transfected cells.  
Figure 34: GFP-sort of pIRES-EGFP, pHsβE- IRES2-EGFP and pHsvβE-IRES2-EGFP transfected HepG2 
and Hep3B cells. Untransfected cells (NTC) were used as negative control in order to determine GFP 
expressing cells.  Green dots in the R2 areas of the dot blots represent GFP-positive cells. Lower panels show 
representative micrographs of Hep3B and HepG2 cells transfected with pIRES-EGFR after GFP-sorting. 
Hep3B-EGFP HepG2-EGFP 
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fluorescence rates (Figure 34). Sorted cells were expanded and on the one hand frozen 
for long term storage and on the other hand subjected to qRT-PCR for expression 
analysis.  
 
 
5.4.2. Lentiviral transduction for long-term silencing of βE 
 
To silence activin E in cell lines with high endogenous βE levels a lentivirus-
mediated knockdown was performed. For that purpose a puromycin kill curve 
(Figure 35) was generated for the cell lines selected for knockdown and the cell 
viability was examined with an MTT assay. The minimum concentration of 
puromycin that caused 90-100% cell death was determined for selection of stable 
clones. We decided to use 0.6 μg/ml puromycin for HepG2 cells and 0.4 μg/ml for 
K562 cells.  
 
 
 
 
 
 
 
 
After that HepG2 and K562 cells were transduced with a range of volumes (2-5 μl) of 
lentiviral particles for βE knockdown and with lentiviral particles expressing 
scrambled shRNA, which served as controls. Puromycin resistant clones were 
subjected to qRT-PCR to inspect the knockdown efficiency.  
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Figure 35: Various concentrations (0.1, 0.2, 0.4, 0.6, 0.8 and 1 µl/ml) of puromycin were 
tested on HepG2 and K562 cells to determine conditions for selection of stable clones. 
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5.4.3. Expression anlaysis of stable clones 
 
5.4.3.1. Analysis of βE overexpression in Hep3B and HepG2 cells 
For a quantitative analysis the relative expression of Activin E in HepG2 and Hep3B 
cells was determined on the RNA level by qRT-PCR by either the TaqMan or SYBR 
green method respectively. Fold expression and Log 2 ratio values are shown in 
figure 36.   
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Figure 36: Expression analysis by qRT-PCR of Activin E in HepG2 and Hep3B cells after transfection, 
selection and establishment of stable clones.  
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Values were determined relative to the mock control. Activin E expression was 
normalized in regard to the expression level of the house-keeping gene β2M. We 
achieved a high over-expression of activin βE, in fact an overexpression of 400 fold in 
Hep3B and still 20 fold in HepG2 cells.  
 
 
5.4.3.2. Analysis of βE silencing in K562 and HepG2 cells  
 
In HepG2 and K562 cells a lentivirus mediated knockdown of activin βE was 
observed by means of qPCR. Relative to the scrambled control we achieved an 
activin βE silencing efficiency of 75% in HepG2 cells, and of 90% in K526 cells (Figure 
37).  
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Figure 37: Expression analysis by qRT-PCR of Activin E in K562 and HepG2 cells after silencing, 
selection and establishment of stable clones.  
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HepG2 cells have compared to Hep3B and K562 cells a medium level of activin βE 
expression, and therefore were used for overexpression as well as for silencing of 
activin βE. Like in multiple other leukemia cell lines, K562 cells were reported to 
have elevated activin E levels compared to healthy bone marrow cells (Rodgarkia-
Dara, personal communication) and therefore we selected this cell line for 
knockdown of activin E. 
 
5.5. Functional characterization of stable clones 
 
In order to determine consequences of increased or decreased activin E levels several 
functional assays were conducted with the generated stable clones.  
5.5.1. Proliferation 
 
5.5.1.1. MTT 
 
For viability testing MTT assays were performed with stable clones under normal 
and reduced serum conditions to investigate whether activin E stimulates or inhibits 
proliferation. We did not observe a strong advantage or disadvantage of βE 
expression compared to the mock control (Figure 38). There was no anti-proliferative 
effect obtainable in βE overexpressing Hep3B cells. Similar results were obtained for 
knockdown of βE, which had also no significant effect on the viability of K562 cells. 
Activin E silenced as well as overexpressing HepG2 cells seemed to have a reduced 
viability in medium with 10% FCS, but as this effect was observed in both cases it is 
unclear how the effect relates to the βE expression level.  
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Figure 38: Cell viability of stable clones with elevated or decreased βE levels under low and normal serum 
concentrations.  
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5.5.1.2. Casy 
 
For proliferation assay of activin E overexpressing cell lines cells were seeded at low 
density and cell number was determined every 2 days with the Casy cell counter. 
The experiment was performed in duplicates. Hep3B mock or βE transfected cells 
did not show any difference in the proliferation rate, similar results were observed 
for HepG2 cells. In Figure 39 cell numbers of non-viable cells and viable cells are 
shown as determined by the Casy cell counter. HepG2 cells highly expressing activin 
βE seem to demonstrate a higher proliferation rate in this assay, but this effect is due 
to seeding of a higher number of βE transfected HepG2 cells at the beginning of the 
experiment. When calculated, HepG2 cells transfected with the mock vector doubled 
with the same factor as βE overexpressing HepG2 cells.  
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Figure 39: Investigation of the proliferation speed of HepG2 
and Hep3B cells with increased βE levels compared to their 
respective mock control.  
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5.5.2.  Clonogenic Survival  
 
To analyze the capability of hepatoma cell lines overexpressing activin E or with 
silenced activin E to form colonies on tissue culture plastic, clonogenic survival 
assays were performed. After the desired clone sizes were obtained the cells were 
stained with crystal-violet (Figure 40).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40: Clonogenicity assay of Hep3B and HepG2 cells: Activin E decreases clone size whereas 
silencing of activin E leads to fewer but bigger clones. Lower row: Photometrical measurement of crystal 
violet and extinction values.  
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The number and size of the clones differed, the higher the βE expression levels the 
smaller were the colonies. βE silenced cells showed a reduced number but bigger 
colonies. This effect was especially noticeable in HepG2. When we solubilized the 
crystal-violet for quantification and measured the absorption photometrically we 
could verify our findings just for the βE overexpressing Hep3B and HepG2 cells but 
not for βE silenced HepG2 (see Discussion section).  
 
5.5.3. Cell cycle  
 
To elucidate whether high activin E levels induce alterations in the distribution of the 
cell cycle phase, cells were stained with propidium-iodide and subjected to flow 
cytometric analysis. An effect of activin E overexpression in HepG2 and Hep3B cells 
leading to cell cycle alterations was undetectable; there was no obvious increase or 
decrease in any cell cycle phase compared to the mock controls (Figure 41).  
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Figure 41: Influence of elevated activin E levels on the cell cycle phase distribution. Cell 
models are compared to mock controls. Experiments were performed in duplicates. 
 
 As we could not see any obvious effects of decreased or increased βE levels on 
proliferation and viability, we further determined the effects on migration. Migratory 
phenotype was analyzed by a wound healing assay and a transwell assay. For the 
wound healing assay confluent cell monolayers were scraped with a pipette tip and 
the closure of the scratches was monitored for a certain time until the scratch was 
completely closed. βE overexpressing cells behaved similar to mock transfected cells 
in the scratch assay (Figure 42
seemed to migrate faster than the mock control when monitored at the 8h measuring 
point. However after 24 hours the wound closure was still not complete compared to 
the mock control. Conversely
the transwell assay and demonstrated a higher ability in passing the membrane 
(Figure 43). Those cells, which were able to migrate through the transwell filter and 
settle on the bottom were stained w
solubilized with SDS the results could be further confirmed. 
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Figure 42: Hep3B cells with elevated βE levels
migration in a scratch assay and compared to mock control
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The Soft Agar assay which was performed to investigate anchorage
growth in three-dimensiona
assay. Cells were incubated for one month and clone formation w
microscopy. Results showed significant differences in anchorage independent 
growth. Higher βE levels led to reduced clone sizes
stronger in HepG2 cells where the βE silenced clones were able to create 
clones. Results clearly showed the impact of activin 
growth behavior of hepatoma cell lines. 
 
Figure 43: Hep3B cells with elevated βE levels were tested for migration through a porous membrane and compared 
to mock control. Cells on the bottom of the well were stained with crystal violet and documente
Subsequently the dye was solubilized and 
duplicates.  
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5.5.5.  Soft Agar  
l culture revealed similar results as the clonogenicity 
 (Figure 44). Again this effect was 
βE on anchorage independent 
 
Hep3B- Transwell
Mo
ck ßE
0.00
0.02
0.04
0.06
0.08
0.10
*
ex
tin
ct
io
n
absorption determined photometrically. Experiments were performed in 
-independent 
as monitored by 
even bigger 
d via photography. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hep3B: 
HepG2: 
Figure 44: Two hepatoma cell lines wit
anchorage independent growth in a soft agar assay. Experiments were done twice in duplicates. 
93 
 
 
 
 
 
 
 
 
 
 
 
 
 
h elevated or decreased activin E levels investigated for 
βE expression level
βE expression level
 
: 
: 
+ 
+ 
- 
- 
94 
 
5.6. Transcriptome analysis: Microarray  
 
Previous discoveries of our research group suggested that activin E does not signal 
via activin A receptors in contrast to activin A. For that purpose HepG2 cells were 
treated with activin E- or activin A-containing conditioned medium. SMAD2 
phosphorylation was analyzed by Western blotting and was only achieved after 
treatment with Activin A-conditioned medium. Thus we performed expression 
arrays to investigate potential activin E target genes and potential pathways activin E 
might be involved in.  
 
Tables 17-23 show the most strongly upregulated or downregulated genes in βE 
overexpressing or silenced cells.  
 
 
Table 17: Genes with the strongest upregulation in βE overexpressing Hep3B cells 
compared to mock control (p-cut off: 0.005) 
Fold change  Gene Symbol Gene Name 
72.192.326 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 
58.520.384 SPON2 spondin 2, extracellular matrix protein 
37.972.121 ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) 
29.477.897 LOC284561 hypothetical protein LOC284561 
29.218.118 DOK3 docking protein 3 
28.554.983 INPP4B inositol polyphosphate-4-phosphatase, type II, 105kDa 
25.692.537 NNMT nicotinamide N-methyltransferase 
25.187.178 OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 
24.525.285 RFTN1 raftlin, lipid raft linker 1 
22.899.847 C1S complement component 1, s subcomponent 
22.878.456 C11orf86 chromosome 11 open reading frame 86 
22.334.228 PTPRE protein tyrosine phosphatase, receptor type, E 
20.989.166 SERPINB9 
serpin peptidase inhibitor, clade B (ovalbumin), member 
9 
20.125.532 C9orf150 chromosome 9 open reading frame 150 
16.620.596 HNMT histamine N-methyltransferase 
14.762.904 PRDM13 PR domain containing 13 
14.063.863 CCL2 chemokine (C-C motif) ligand 2 
8.138.984 PACSIN1 protein kinase C and casein kinase substrate in neurons 1 
7.682.129 IGFBP2 insulin-like growth factor binding protein 2, 36kDa 
6.502.067 RAC2 
ras-related C3 botulinum toxin substrate 2 (rho family, 
small GTP binding protein Rac2) 
5.219.576 VAV3 vav 3 guanine nucleotide exchange factor 
4.341.417 KLRK1 killer cell lectin-like receptor subfamily K, member 1 
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3.608.239 HBE1 hemoglobin, epsilon 1 
2.599.615 CD33 CD33 molecule 
2.422.848 SERPINB8 
serpin peptidase inhibitor, clade B (ovalbumin), member 
8 
 
 
 
Table 18: Genes with the strongest down regulation in βE overexpressing Hep3B cells (p-
cut off: 0.005) compared to mock control 
Fold change Gene Symbol Gene Name 
-78.594.337 PID1 phosphotyrosine interaction domain containing 1 
-75.120.435 KIF26B kinesin family member 26B 
-73.797.584 INHBA inhibin, beta A 
-66.683.493 SLC16A14 
solute carrier family 16, member 14 (monocarboxylic acid 
transporter 14) 
-62.050.586 CHSY3 chondroitin sulfate synthase 3 
-56.006.455 TBC1D8B TBC1 domain family, member 8B (with GRAM domain) 
-48.262.563 PLIN2 perilipin 2 
-47.573.543 CRYAB crystallin, alpha B 
-44.932.456 LY6D lymphocyte antigen 6 complex, locus D 
-43.962.555 MME membrane metallo-endopeptidase 
-42.843.037 FBN1 fibrillin 1 
-41.815.395 OLFML2A olfactomedin-like 2A 
-38.130.786 NEBL nebulette 
-37.900.813 TWIST1 twist homolog 1 (Drosophila) 
-36.724.718 TARSL2 threonyl-tRNA synthetase-like 2 
-34.989.972 MGC5566 hypothetical protein MGC5566 
-34.399.617 PSG2 pregnancy specific beta-1-glycoprotein 2 
-34.361.622 EPHX2 epoxide hydrolase 2, cytoplasmic 
-34.034.517 MAP1B microtubule-associated protein 1B 
-33.903.515 COMP cartilage oligomeric matrix protein 
-30.832.744 TOX thymocyte selection-associated high mobility group box 
-29.068.193 MYLK myosin light chain kinase 
-26.522.336 NEO1 neogenin homolog 1 
-24.479.144 PLCG2 phospholipase C, gamma 2 (phosphatidylinositol-specific) 
-23.219.671 TNFAIP3 tumor necrosis factor, alpha-induced protein 3 
-23.146.129 TSPAN5 tetraspanin 5 
-23.070.517 SESN3 sestrin 3 
-21.198.237 GAB2 GRB2-associated binding protein 2 
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Table 19: Genes with the strongest regulation in βE overexpressing HepG2 cells compared 
to mock control (p-cut off: 0.05) 
Fold change Gene symbol Gene name 
22.154.768 NRP1 neuropilin 1 
7.945.555 SHC3 
SHC (Src homology 2 domain containing) transforming 
protein 3 
-1.306.467 FGF2 fibroblast growth factor 2 (basic) 
-16.511.409 PLK1S1 polo-like kinase 1 substrate 1 
 
 
 
Table 20: Genes with the strongest upregulation in βE silenced HepG2 cells compared to 
scrambled control (p-cut off: 0.05) 
Fold change Gene symbol Gene name 
53.715.982 MATN3 matrilin 3 
46.639.595 CXCR4 chemokine (C-X-C motif) receptor 4 
44.935.265 GATA6 GATA binding protein 6 
43.752.284 RASSF2 Ras association (RalGDS/AF-6) domain family member 2 
38.858.762 AREG amphiregulin 
36.046.255 FGB fibrinogen beta chain 
35.110.023 ATP10A ATPase, class V, type 10A 
34.767.532 LPA lipoprotein, Lp(a) 
34.471.867 ARSI arylsulfatase family, member I 
33.723.102 PLG plasminogen 
30.969.763 TMSL3 thymosin-like 3 
30.884.955 BIK BCL2-interacting killer (apoptosis-inducing) 
29.993.558 SOX8 SRY (sex determining region Y)-box 8 
28.197.937 ODAM odontogenic, ameloblast asssociated 
25.075.233 PDLIM3 PDZ and LIM domain 3 
23.881.536 CSGALNACT1 chondroitin sulfate N-acetylgalactosaminyltransferase 1 
23.362.124 CCDC90B coiled-coil domain containing 90B 
23.251.696 C20orf114 chromosome 20 open reading frame 114 
23.064.346 FXYD2 FXYD domain containing ion transport regulator 2 
22.119.942 SLCO4A1 solute carrier organic anion transporter family, member 4A1 
21.999.533 SLC7A10 
solute carrier family 7, (neutral amino acid transporter, y+ 
system) member 10 
21.594.415 UGT1A6 UDP glucuronosyltransferase 1 family, polypeptide A6 
20.894.046 RCN1 reticulocalbin 1, EF-hand calcium binding domain 
20.676.708 COL5A2 collagen, type V, alpha 2 
20.158.842 DOCK8 dedicator of cytokinesis 8 
20.044.498 RCN1 reticulocalbin 1, EF-hand calcium binding domain 
16.679.701 CDK6 cyclin-dependent kinase 6 
16.627.996 KLF9 Kruppel-like factor 9 
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Table 21: Genes with the strongest down regulation in βE silenced HepG2 cells compared to 
scrambled control (p-cut off: 0.05) 
Fold change Gene symbol Gene name 
-58.684.335 FSTL5 follistatin-like 5 
-39.372.344 KRTAP3-1 keratin associated protein 3-1 
-37.429.242 CDO1 cysteine dioxygenase, type I 
-37.132.442 FGF13 fibroblast growth factor 13 
-36.014.829 COBL cordon-bleu homolog (mouse) 
-35.948.849 LCN15 lipocalin 15 
-35.048.552 AGTR1 angiotensin II receptor, type 1 
-34.252.439 AQP3 aquaporin 3 (Gill blood group) 
-32.355.046 ANKRD1 ankyrin repeat domain 1 (cardiac muscle) 
-31.746.798 C8G complement component 8, gamma polypeptide 
-27.005.363 GSTA2 glutathione S-transferase alpha 2 
-26.594.753 GSTA5 glutathione S-transferase alpha 5 
-25.916.007 LGALS3 lectin, galactoside-binding, soluble, 3 
-25.829.594 EFR3B EFR3 homolog B (S. cerevisiae) 
-24.957.435 ROR1 receptor tyrosine kinase-like orphan receptor 1 
-23.343.658 AOX1 aldehyde oxidase 1 
-22.928.731 KNG1 kininogen 1 
-22.612.743 GSTA1 glutathione S-transferase alpha 1 
-22.089.303 ROR1 receptor tyrosine kinase-like orphan receptor 1 
-22.022.758 FRZB frizzled-related protein 
-21.941.109 IL17B interleukin 17B 
-21.870.906 HSD17B6 hydroxysteroid (17-beta) dehydrogenase 6 homolog (mouse) 
-21.806.164 ADORA2A adenosine A2a receptor 
-21.768.827 CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 
-21.271.157 DYDC2 DPY30 domain containing 2 
-21.041.977 PPARGC1B 
peroxisome proliferator-activated receptor gamma, 
coactivator 1 beta 
-21.002.278 KIAA1211 KIAA1211 
-19.917.067 AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) 
 
 
 
Table 22: Genes with the strongest upregulation in βE silenced K562 cells compared to 
scrambled control (p-cut off: 0.05) 
Fold change Gene symbol Gene name 
87.152.605 TF transferrin 
78.592.567 BCHE butyrylcholinesterase 
69.152.646 ZBTB20 zinc finger and BTB domain containing 20 
67.465.143 ALPK1 alpha-kinase 1 
66.925.416 BMP7 bone morphogenetic protein 7 
65.463.476 LOC728148 hypothetical LOC728148 
61.355.886 FCRLA Fc receptor-like A 
61.327.147 ZNF862 zinc finger protein 862 
57.661.138 TM6SF1 transmembrane 6 superfamily member 1 
53.973.117 ATL1 atlastin GTPase 1 
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47.718.244 FAM9B family with sequence similarity 9, member B 
45.223.513 FMN2 formin 2 
43.956.585 CASP4 caspase 4, apoptosis-related cysteine peptidase 
43.190.796 CSTA cystatin A (stefin A) 
43.172.073 C17orf108 chromosome 17 open reading frame 108 
42.813.964 RGS3 regulator of G-protein signaling 3 
41.411.753 LOC550643 hypothetical LOC550643 
41.039.014 MAGEA9 melanoma antigen family A, 9 
40.224.156 SCAND3 SCAN domain containing 3 
39.737.864 SLC16A9 
solute carrier family 16, member 9 (monocarboxylic acid 
transporter 9) 
38.575.401 TPD52 tumor protein D52 
38.520.043 CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) 
38.081.455 CLIC3 chloride intracellular channel 3 
37.325.654 CDNF cerebral dopamine neurotrophic factor 
37.228.332 MAGI2 
membrane associated guanylate kinase, WW and PDZ domain 
containing 2 
37.002.301 ZNF618 zinc finger protein 618 
36.347.253 A2LD1 AIG2-like domain 1 
36.286.764 NEBL nebulette 
36.170.127 SCAND3 SCAN domain containing 3 
 
 
Table 23: Genes with the strongest down regulation in βE silenced K562 cells compared to 
scrambled control (p-cut off: 0.05) 
Fold change Gene symbol Gene name 
-44.321.256 ARHGAP22 Rho GTPase activating protein 22 
-41.625.404 ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 
-34.202.886 MYBBP1A MYB binding protein (P160) 1a 
-31.906.345 PRG2 
proteoglycan 2, bone marrow (natural killer cell activator, 
eosinophil granule major basic protein) 
-31.674.523 TRMT61A tRNA methyltransferase 61 homolog A (S. cerevisiae) 
-28.635.979 POLR3H polymerase (RNA) III (DNA directed) polypeptide H (22.9kD) 
-27.985.365 SLC19A1 solute carrier family 19 (folate transporter), member 1 
-27.255.046 NOLC1 nucleolar and coiled-body phosphoprotein 1 
-26.329.486 COL1A2 collagen, type I, alpha 2 
-25.463.548 DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1 
-24.092.095 LYPLA2 lysophospholipase II 
-22.458.973 POLR2L polymerase (RNA) II (DNA directed) polypeptide L, 7.6kDa 
-21.855.948 AQP3 aquaporin 3 (Gill blood group) 
-21.246.884 RASGEF1A RasGEF domain family, member 1A 
-20.812.352 POLR1E polymerase (RNA) I polypeptide E, 53kDa 
-20.643.992 PUS7 pseudouridylate synthase 7 homolog (S. cerevisiae) 
-20.553.267 CTRL chymotrypsin-like 
-20.490.353 PPRC1 
peroxisome proliferator-activated receptor gamma, 
coactivator-related 1 
-19.739.822 FYB FYN binding protein (FYB-120/130) 
-19.581.864 ZC3HAV1 zinc finger CCCH-type, antiviral 1 
-19.254.731 CTSC cathepsin C 
-19.162.354 QRSL1 glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1 
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-18.998.454 WDR36 WD repeat domain 36 
-18.882.649 FOXRED2 FAD-dependent oxidoreductase domain containing 2 
-18.870.491 CXorf15 chromosome X open reading frame 15 
-18.863.871 RRN3 
RRN3 RNA polymerase I transcription factor homolog (S. 
cerevisiae) 
-18.391.569 NOL12 nucleolar protein 12 
-18.222.562 FBXO45 F-box protein 45 
-18.150.611 SURF6 surfeit 6 
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6. Discussion 
 
6.1. Establishment of activin E expression vectors for 
generation of stable clones 
 
The central aim of this diploma thesis was to clarify how activin E functions in 
malignant cells. For that purpose on the one hand we carried out overexpression of 
activin E in low endogenous activin E-expressing Hep3B cells and HepG2 cells with 
medium activin E levels. Prior to transfection bicistronic expression vectors were 
generated containing an IRES sequence and verified by molecular sequencing which 
confirmed the absence of mutations. On the other hand we knocked down activin E 
in K562 leukemia cells with high endogenous activin E levels and in HepG2 cells. 
Thus in HepG2 we could compare knockdown and overexpression in the same cell 
model. Knockdowns were performed by sh-lentiviruses which were purchased 
commercially.  
HepG2 and Hep3B hepatoma cell lines were transfected with vectors pHsβE-IRES-
EGFP, pHsvβE-IRES-EGFP and the empty vector control pIRES-EGFP via lipofection 
to generate stable clones, because most of the previous data till now were gained by 
transient overexpression. Unlike untransfected cells, successfully transfected HepG2 
and Hep3B cells were GFP-positive as all vector constructs (except the commercial 
shRNA expression constructs) carried the GFP-gene. Hence it was possible to 
determine the transfection efficiency via fluorescence microscopy and subject clones 
for selection to GFP-sort. The transfection efficiency was high of the empty vector 
and the βE construct. It could be observed that for the used hepatoma cell lines 
transfection efficiencies of 30-50% for pIRES-EGFP and pHsβE-IRES-EGFP 
respectively were obtained, but 0-1% for pHsvβe-IRES-EGFP. In previous 
experiments it was shown that cloning of vβE was not an easy task (Michael Grusch, 
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personal communicaiton), even when we sorted almost 1% GFP positive cells and 
expanded them, the cells lost GFP expression shortly afterwards. For this reason we 
treated vβE transfected cells with 5´azacytidine, which is a demethylating agent, and 
investigated if there is an epigenetic regulation of this gene. vβE transfected cells 
were treated with 5´azacytidine and non-treated vβE-expressing cells served as 
controls. Subsequently fluorescence was monitored for several days. Cells slightly 
gained back their fluorescence but also untreated control cells fluoresced at a very 
low rate. This effect might be due to the fact that the cells were not subjected to 
splitting during the experiment; however the fluorescence rate of vβE-transfected 
cells was still not indicative of a significant expression of the bicistronic transcript. 
Hence we decided to focus on the βE overexpressing and silenced cells.  
 After successful cloning and sorting, expression of βE in stable clones was verified 
by using qPCR and we achieved an overexpression of 400 fold in Hep3B and 20 fold 
in HepG2 cells. The differences in the overexpression levels might be due to the fact 
that the HepG2 cell line expresses endogenously far more Activin E than Hep3B cells. 
Untransfected HepG2 cells have an Activin E CT value of 25 whereas Hep3B cells 
have a CT of 30 (the CT values of the respective housekeeping genes range between 
20-21 for both cell lines). However even in the cells with the highest ectopic  
overexpression (Hep3B) we do not exceed the level found in cells endogenously 
expressing high levels of activin βE such as normal hepatocytes.  
For silencing, K562 leukemia cells and HepG2 hepatoma cells were cultured and 
transduced with sh-lentiviruses targeting activin βE and with scrambled sh control. 
After transfection, stable clones were obtained by antibiotic selection and the 
expression level was determined by qRT-PCR which demonstrated a successful 
knockdown of activin E.  
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6.2. Expression of Histidin-tagged activin E and A 
 
Successful purification and quantification of activin E is a prerequisite for testing of 
potential target receptors. In order to investigate the effects of activin E, an 
expression system was created for a 6xhistidin-tagged version, since activin E protein 
is not available commercially.  Expression of activin A in SF9 cells was shown 
previously by Wuytens et al. (1999) but this approach has not been tested for activin 
E. Our results suggest that SF9 cells as expression system are not suitable for the 
synthesis of recombinant activins. We did not achieve bioactivity of His-tagged 
activin A proteins, although they were able to form dimers and were detectable by 
Western Blot analysis. A CHO expression system could be more capable to produce 
activin E, based on previous reports of the production of bioactive activin A by the 
CHO expression system (Wada et al., 2004; Arai et al., 2006). In fact production and 
EtOH precipitation of activin A was not a complicated task, as with commercially 
available antibodies against either the histidin tag or against activin A the produced 
proteins were detectable. However 6xhistidin was detectable in activin E expressing 
cells only when gels were run under reducing conditions before immunoblotting. It 
has to be evaluated which factor is responsible for the lack of bioactivity in our 
system. Based on these findings we reason that another expression system may be 
required for optimizing an approach to produce and purify recombinant activin E.  
6.3. Biological effects of activin E overexpression or 
silencing 
Stable clones with decreased or increased activin E levels were consequently used for 
functional tests and the whole transcriptome was analyzed via expression arrays. The 
phenotypic differences when activin E levels lessen or were increased were analyzed 
by different assays. Phenotypic properties such as proliferation (obtained by CASY 
measurement), viability (MTT assay), clonogenicity (clonogenic survival assay), cell 
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cycle status (FACS analysis), migration (by wound healing and transwell assay) and 
anchorage independent growth (Soft agar assay) were monitored and investigated 
for different time periods.  
Results of functional tests assessing short-term viability and proliferation did not 
demonstrate any obvious effects of decreased or increased βE levels, the proliferation 
rate was quite similar. When we incubated stable clones under reduced serum 
compared to normal serum conditions we did not monitor a strong advantage or 
disadvantage of βE expression compared to the mock control. By contrast 
experiments assessing anchorage-independent growth in three-dimensional cultures 
clearly demonstrated that the higher the βE expression levels the smaller were the 
colonies. This effect was stronger in HepG2 cells where the βE silenced clones could 
create bigger clones in contrast to βE overexpressing cells which could not build up 
clones about a certain threshold. The soft agar assay, which can be considered to be 
an in-vivo-like assay, illustrates the tumorigenic properties of cells. Similar results 
were obtained when we analyzed the capability of single cells to form colonies on 
tissue culture plastic. In these so called clonogenic survival assays we found that the 
number as well as clone sizes differed between mock transfected and βE transfected 
cells, in fact βE silenced cells showed a reduced number but bigger size of clones. 
This effect was again stronger in assays performed with HepG2 cells. When we 
measured crystal violet photometrically we could verify our findings only for the βE 
transfected HepG2 and Hep3B cells but not for our silenced HepG2 cells. To 
solubilize crystal violet from HepG2 cells was not an easy task due to the growth of 
HepG2 cells in tight multilayered colonies. This can be considered as one reason for 
our photometric results. On the other hand the observation was that the more βE the 
cells expressed the higher the number of (small) obtained clones was. The clonogenic 
assay addresses on the one hand survival at low density and on the other hand the 
ability to form colonies due to proliferation fitness. Even when βE silenced clones 
created bigger clones due to their proliferation advantage they might have 
difficulties in adhering and to survive at low density.  
104 
 
Latter results don’t confirm our findings in proliferation and viability gained by Casy 
measurement and MTT assays where we could not detect differences between clones 
and controls. Reasons for that could be on the one hand that in the proliferation and 
viability assays cells were monitored only for a relatively short time period of 5-8 
days compared to the clonogenic assay which was incubated 2 weeks and the soft 
agar assay which was allowed to develop for at least 4 weeks. The longer the assay 
lasted the stronger were the effects. On the other hand it has to be considered that 
during investigation of the cumulative cell number the possibility for technical 
problems is higher, cells might have responded differently due to repeated splitting 
and reseeding. Conflicting results regarding the impact of activin E on proliferation 
were also found in previous results from other research groups, e.g. HepG2 cells 
treated with activin E-conditioned medium did not demonstrate any effects on cell 
proliferation (Hashimoto et al., 2009), whereas transient expression of βE in HepG2 
reduced cell number and induced apoptosis (Vejda et al., 2003).  
Interestingly we also see a slight impact of activin βE on the migration of cells. When 
confluent cell monolayers were scraped with a pipette tip and the closure of the 
scratches was monitored for a certain time, βE overexpressing cells seemed to fill the 
gap more rapidly, when quantified in percentage there was a difference of more than 
10% gap closure after 8 hours of incubation. This trend was not sustained, however, 
since after 24 hours the mock control but not the βE overexpressing cells could close 
the gap completely. Significant differences between mock and βE transfected cells 
were observed in the transwell assay, where βE overexpressing cells showed a higher 
ability in passing the membrane. If we solubilized the crystal violet with SDS the 
results could be further confirmed. Here it has to be kept in mind that the transwell 
assay is incubated only for a relative short time, especially in the case of the highly 
proliferative Hep3B cells, to allow only a low number of cells to drop into the well, 
and thus might demonstrate short term effects. Additionally it has to be 
distinguished between the ability of cells to pass through a membrane and to migrate 
laterally as in the wound healing assay.   
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6.4. Transcriptome analysis and investigation of target 
genes of activin E 
 
As already mentioned in the introduction Activin A, B and heterodimers AB initiate 
their biological activity, like most members of the TGF-β superfamily, through type I 
and type II transmembrane (serine/threonine) kinase receptors whereof various 
isoforms exist. Further they activate downstream signaling effectors the so called 
SMADs and regulate target gene expression. These findings could not be 
demonstrated for activin E in previous results of our research group and thus 
signaling mechanisms of activin E need further investigation.  
 
Expression analysis revealed some strongly regulated genes when βE overexpressing 
and silenced cells were compared to their respective controls. When activin E levels 
were elevated in Hep3B cells genes involved in apoptosis were strongly regulated. 
TNFSF10 (tumor necrosis factor (ligand) superfamily, member 10) for instance, which 
belongs to the tumor necrosis factor family induces apoptosis in tumor cells. 
Additionally it triggers the activation of caspase 8, caspase 3 and MAPK8/JNK 
(Kuribayashi et al., 2008). We obtained a 70 fold upregulation of TNFSF10 in Hep3B 
cells with elevated βE levels. As another indication of apoptosis regulation we 
detected that TNFAIP3 (tumor necrosis factor, alpha-induced protein 3) gene 
expression was 23 fold downregulated. This gene, which is regulated by TNF is 
known to inhibit TNF-mediated apoptosis and NF-kappa B activation (Nino Fong et 
al., 2011). These observations support the thesis that activin E overexpression leads to 
reduced proliferation and induction of apoptosis (Vejda et al., 2003; Wada et al., 
2005). Gab 2 (GRB2-associated binding protein) was also one of the strongly down 
regulated genes in βE overexpressing Hep3B cells (21 fold). Gab2 down-regulation 
by RNA interference is known to strongly abrogate cell growth in soft agar (Mira A. 
et al., 2009), consistent with our soft agar experiments where βE overexpressing cells 
demonstrated reduced proliferation. Interestingly TWIST1 (twist homolog 1) is 
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strongly downregulated in βE expressing Hep3B cells. Twist is known to promote 
EMT (epithelial to mesenchymal transition) and tumor metastasis together with Snail 
2. EMT is a process, which leads in vivo to metastatic growth, because of increased 
motility and invasiveness of the cells (van Zijl et al., 2011). Although we could not 
observe a less migratory capability of βE overexpressing cells in the transwell assay, 
we observed impaired motility of βE transfected cells in the wound healing assay, 
where βE transfectants could not completely fill the gap in contrast to the mock 
control. Nevertheless it has to be kept in mind that EMT is not the only mechanism of 
migration.  
NEO 1 (neogenin homolog 1) is also strongly decreased in activin E overexpressing 
cells. Neogenin is a known receptor of bone morphogenetic proteins and 
consequently modulates SMAD signaling (Hagihara et al., 2011). The most 
interesting gene which was heavily downregulated in Hep3B cells when βE levels 
were elevated is activin βA where we obtained a 74 fold down regulation. This could 
mean that there is a feed-back loop connecting these two activin subunits, despite the 
fact that in previous results of our research group activin E did not block activin A 
signaling. The crosstalk between these two cytokines has to be further investigated.  
In HepG2 cells overexpressing activin E some members of the VEGF signaling 
pathway were upregulated. Unlike in activin E silenced HepG2 cells we did not 
obtain many regulated genes in βE transfected HepG2. Activin E silenced HepG2 
cells demonstrated elevated levels of GATA 6 (gata binding protein 6) which 
promotes survival and angiogenesis in endothelial cells. Additionally GATA 6 
protects from apoptosis, and it was shown that overexpression of GATA 6 
suppressed the activity of the TGF-beta 1 promoter (Froese et al., 2011). 
Amphiregulin (AREG) which is a EGF-receptor ligand and related to TGF-α, is 
strongly upregulated in activin E silenced HepG2 cells. AREG expression in 
cancerous tissue is connected to apoptosis-resistance, high replication rate, metastasis 
and invasive behavior to mention some (Busser et al., 2011). Elevated AREG 
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expression could contribute to the increased anchorage-independent growth 
observed for HepG2 cells with silenced βE in this study. 
 
K562 leukemia cells have elevated levels of activin E in contrast to hepatoma cells. By 
this reason we were interested in the phenotype of these cells when we knocked 
down activin E. As shown in Hep3B cells which in contrast were brought to 
overexpress activin E, also in silenced K562 cells we found the same observation that 
apoptosis inducing genes such as Casp4 were upregulated. Additionally we found 
that bone morphogenetic protein 7 (BMP7), which is a member of the TGF-β family, 
was strongly upregulated (66 fold). Regulation of the expression of other TGF- β 
family members is suggested as one of the roles of activin E.    
The determination of the functions of activin E is still rather difficult. Taking all 
results together activin E crosstalks with various signaling pathways but cannot be 
connected to a certain receptor. Activin E seems to modulate signaling of related 
cytokines, and reduce proliferation in hepatoma cells, which was also shown for the 
related cytokine activin A (Deli et al., 2008). However the expression arrays need 
further evaluation, genes regulated in the expression arrays have to be validated 
with other methods and a new approach to produce recombinant activin E has to be 
established.  
 
 
 
 
 
 
 
108 
 
7. Appendix 
 
7.1. List of figures 
 
Figure 1: Schematic overview of SMAD-dependent TGF-β signaling (Schmierer et al., 2007). ______ 16 
Figure 2: Dimer formation of activins and inhibins: activins are made up of two β subunits; inhibins 
are formed by dimerization between one β and one α subunit. Adapted from (Phillips et al., 2009). 19 
Figure 3: Dimer formation of activin: the dimerized propeptide is enzymatically cleaved to produce 
the mature peptide (Phillips et al., 2009). ___________________________________________________ 19 
Figure 4: TGF-β superfamily ligands, receptor isoforms and corresponding downstream effector 
SMADs (downloaded from: http://www.biologie.uni-
regensburg.de/Biochemie/Deutzmann/Signal_WS/TGF_SigTrans_web.pdf; accessed 2011-06-29). __ 22 
Figure 5: Synthesis of activin E and dimerization possibilities with other activin subunits. (Emanuel 
Kreidl, Diploma Thesis at the University of Vienna, 2008). ____________________________________ 25 
Figure 6: Template vector pIRES-HsAβE containing the human βE-subunit. ____________________ 64 
Figure 7: pIRES-EGFP target vector and mock control. _______________________________________ 64 
Figure 9: Plasmid preparation and restriction of two possible clones with respectively SnaBI, HindIII 
or EcoR47III: Lane 1: 1kB Marker, Lane 2: unrestricted plasmid DNA of clone 1, Lane 3: clone 1-SnaBI 
restriction, Lane 4: clone 1-HindIII, Lane 5: clone 1- Eco47III, Lane 6: unrestricted plasmid DNA of 
clone 2, Lane 7: clone 2-SnaBI restriction, Lane 8: clone 2-HindIII restriction, Lane 9: clone 2-Eco47III 
restriction (1% agarose gel in 0.5x TBE). ____________________________________________________ 64 
Figure 8: Preparative agarose gel: Lane 1: pIRES-HsAβE vector restricted with NdeI and EcoRI (50 μl 
DNA + 10 μl VistraGreen), Lane 2: pIRES-HsAβE unrestricted, Lane 3: 1kB Marker, Lane 4: pIRES-
EGFP restriction by NdeI and EcoRI, (1% agarose gel in 0.5x TBE). _____________________________ 64 
Figure 10: Nucleotide sequencing report: Alignment analysis based on sequencing report results and 
pIRES-HsAβE vector as reference, and subsequent chromatographic analysis of undefined (“n”, see 
red arrows) bases for point mutation. ______________________________________________________ 65 
Figure  11:  Cloning product vector pHsβE-IRES-EGFP. ______________________________________ 65 
Figure 12: pCMV-Sport6-altβE vector containing the alternative βE subunit. ____________________ 67 
Figure 14: Vector pIRES-EGFP restriction digest with BamHI and EcoRI: Lane 1: pIRES-EGFP 
restriction, Lane 2: pIRES-EGFP unrestricted, Lane 3: 1kB Marker, (1% agarose gel in 0.5 x TBE) ___ 67 
Figure 13:  PCR amplification of vβE subunit with Pfu-polymerase: Lane 1: 1kB Marker, Lane 2-5: PCR 
product, (1% agarose gel in 0.5x TBE). _____________________________________________________ 67 
Figure 15: Plasmid “quick-preparation” of eight clones and restriction with respectively HindIII or 
Eco47III to screen for potential positive clones containing pvβE-IRES-EGFP vector: Lane 1: 1kB 
Marker, Lane 2-9: Eco47III restricted plasmids of different clones, Lane 10: empty, Lane 11-16: HindIII 
109 
 
restriction approaches with same plasmids gained by same clones, Lane 17: 1kB Marker, Lane 18-20: 
HindIII restriction, (1% agarose gel in 0.5x TBE). ____________________________________________ 68 
Figure 16: Nucleotide sequencing report: Alignment analysis based on sequencing report results and 
pCMV-SPORT6-altβE vector as reference, and subsequent chromatographic analysis of undefined 
(“n”, see red arrows) bases for point mutation. ______________________________________________ 68 
Figure 17: newly constructed fusion product: vector pHsvβE-IRES-EGFP. ______________________ 68 
Figure 18: (a) Vector pTet-Off Advanced expresses constitutively the tetracycline-controlled 
transcriptional transactivator. (b) Vector pTRE-Tight contains the inducible promoter that controls the 
transcription of the gene of interest. _______________________________________________________ 70 
Figure 19: Control restriction of newly generated pTet-Off-TRE-Tight with HpaI: Lane 1: 1kB Marker, 
Lane 2: empty, Lane 3: HpaI restricted clone. Expected fragment sizes of 414 bp, 2875 bp, and 4450 bp 
were obtained and indicate an antisense orientation of insertion of insert DNA. _________________ 71 
Figure 20: Newly generated vector pTet-Off-TRE-Tight. ______________________________________ 71 
Figure 21: Control restriction of newly generated pTet-Off-TRE-Tight-EGFP: Lane 1: 1kB Marker, Lane 
2: NotI and KpnI double digestion of clone with expected fragment sizes of 756 bp and 7695 bp, Lane 
3: EcoRI restriction of clone with expected fragment sizes of 2216 bp and 6235 bp. _______________ 71 
Figure 22: Newly generated vector pTet-Off-TRE-Tight-EGFP. ________________________________ 71 
Figure 23: Control restriction with EcoRI enzyme: Lane 1: 1kB, Lane 2-4: three different clones 
digested with EcoRI. ____________________________________________________________________ 73 
Figure 24:  Cloning product vector pTet-Off-TRE-Tight-HsvβE. _______________________________ 73 
Figure 25: Schematic overview of the Bac to Bac expression system (Bac-to-Bac Expression Kit 
Handbook, Invitrogen life technologies). ___________________________________________________ 74 
Figure 26: For production of recombinat activin E or A two different approaches were conducted. In 
the first approach the recombinant protein was HIS-tagged between the pro- and mature peptide, and 
in the second approach at the C-terminal end of the mature peptide. ___________________________ 75 
Figure 27: (a) Vector pHsaβE was used as PCR template for construction of His-tagged activin βE. (b): 
Vector pHsINHBA-IRES-puro was used as PCR template for construction of His-tagged activin βA. 76 
Figure 28: Control restrictions of plasmid minipreparations: Lane 1+14: 1kB Marker, Lane 2-7: 
His_INHBE restricted with SnaBI, Lane 8-15: INHBE_His restricted with SnaBI, Lane 16-23: 
INHBA_His restricted with HindIII. Red arrows indicate fragments of expected length after restriction 
which were 1300 bp in the case of activin A cassettes and 1100 bp in the case of activin E constructs. 77 
Figure 30: Control restrictions of plasmid minipreparations: Lane 1: 1kB Marker, Lane 2-7: INHBE_His 
construct restricted with SnaBI. Red arrows indicate fragments of expected length after restriction 
which was 1100 bp. _____________________________________________________________________ 78 
Figure 29: Control restrictions of plasmid minipreparations: Lane 6: 1kB Marker, Lane 1-5 + 7-10: 
His_INHBA construct restricted with HindIII. Red arrows indicate fragments of expected length after 
restriction which was 1300 bp. ____________________________________________________________ 78 
Figure 31: Microscopy of SF9 insect cells expressing recombinant activin and YFP. _______________ 79 
110 
 
Figure 32: Western Blot analysis of recombinant activin A or E. Transfected SF9 cells were incubated 
in serum-free medium (SFM) and after baculovirusoutbreak, which was visible under the microscope 
due to YFP expression, supernatant was precipitated with EtOH and protein-samples subjected to 
Western Blotting. Detection of protein with activin A antibody (a) or histidin antibody (b). 
Supernatant of SF9 cells expressing recombinant protein into SFM medium was transferred to HepG2 
cells and incubated for 30 min. Proteins were isolated from the cell layer and recombinant activin 
bioactivity was analyzed using anti-pSMAD2 antibody (c). ___________________________________ 80 
Figure 33: Transfection efficiency of pIRES-EGFP and pHsvβe-IRES2-EGFP transfected cells. ______ 82 
Figure 34: GFP-sort of pIRES-EGFP, pHsβE- IRES2-EGFP and pHsvβE-IRES2-EGFP transfected 
HepG2 and Hep3B cells. Untransfected cells (NTC) were used as negative control in order to 
determine GFP expressing cells.  Green dots in the R2 areas of the dot blots represent GFP-positive 
cells. Lower panels show representative micrographs of Hep3B and HepG2 cells transfected with 
pIRES-EGFR after GFP-sorting. ___________________________________________________________ 82 
Figure 35: Various concentrations (0.1, 0.2, 0.4, 0.6, 0.8 and 1 μl/ml) of puromycin were tested on 
HepG2 and K562 cells to determine conditions for selection of stable clones. ____________________ 83 
Figure 36: Expression analysis by qRT-PCR of Activin E in HepG2 and Hep3B cells after transfection, 
selection and establishment of stable clones. ________________________________________________ 84 
Figure 37: Expression analysis by qRT-PCR of Activin E in K562 and HepG2 cells after silencing, 
selection and establishment of stable clones. ________________________________________________ 85 
Figure 38: Cell viability of stable clones with elevated or decreased βE levels under low and normal 
serum concentrations. ___________________________________________________________________ 87 
Figure 39: Investigation of the proliferation speed of HepG2 and Hep3B cells with increased βE levels 
compared to their respective mock control. _________________________________________________ 88 
Figure 40: Clonogenicity assay of Hep3B and HepG2 cells: Activin E decreases clone size whereas 
silencing of activin E leads to fewer but bigger clones. Lower row: Photometrical measurement of 
crystal violet and extinction values. _______________________________________________________ 89 
Figure 41: Influence of elevated activin E levels on the cell cycle phase distribution. Cell models are 
compared to mock controls. Experiments were performed in duplicates. _______________________ 90 
Figure 42: Hep3B cells with elevated βE levels were tested for migration in a scratch assay and 
compared to mock control. Wound closure in percent is depicted in the graph. Experiments were 
performed in duplicates. _________________________________________________________________ 91 
Figure 43: Hep3B cells with elevated βE levels were tested for migration through a porous membrane 
and compared to mock control. Cells on the bottom of the well were stained with crystal violet and 
documented via photography. Subsequently the dye was solubilized and absorption determined 
photometrically. Experiments were performed in duplicates. _________________________________ 92 
Figure 44: Two hepatoma cell lines with elevated or decreased activin E levels investigated for 
anchorage independent growth in a soft agar assay. Experiments were done twice in duplicates. __ 93 
 
 
 
„Ich habe mich bemüht, sämtliche Inhaber der Bildrechte ausfindig zu 
machen und ihre Zustimmung zur Verwendung der Bilder in dieser Arbeit 
eingeholt. Sollte dennoch eine Urheberrechtsverletzung bekannt werden, 
ersuche ich um Meldung bei mir.“ 
111 
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ALK   activin receptor-like kinase  
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BMP   bone morphogenetic protein 
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DMSO   Dimethyl sulfoxide 
EDTA   ethylenediaminetetraacetic acid 
FACS   fluorescence-activated cell sorting 
FCS   fetal calf serum  
FLRG   follistatin-related gene  
FSH   follicle stimulating hormone 
Fst   Follistatin 
GAPDH  glyceraldehyde-3 phosphate dehydrogenase 
GDF   growth and differentiation factor 
HCC   hepatocellular carcinoma 
MIS    Muellerian inhibiting substance 
MTT   dimethyl thiazolyl diphenyl tetrazolium salt 
PBS   phosphate buffered saline  
PVDF   Polyvinylidene fluoride 
PVN    paraventricular axis 
RT-PCR   reverse transcriptase polymerase chain reaction 
SDS   sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulphate polyacrylamide gel electrophoresis 
TBS   Tris buffered saline 
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TBST   Tris buffered saline with 0.1% Tween-20 
TE   Tris EDTA buffer solution 
TEMED  N,N,N’,N’–tetramethylethylenediamine 
TGF-β    Transforming growth factor beta 
VLDLR   very low density lipoprotein receptor 
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